Document and Entity Information
Document and Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2019 | Mar. 25, 2020 | Jun. 30, 2019 | |
Document and Entity Information [Abstract] | |||
Document Type | 10-K/A | ||
Amendment Flag | false | ||
Document Period End Date | Dec. 31, 2019 | ||
Entity Registrant Name | IntelGenx Technologies Corp. | ||
Entity Central Index Key | 0001098880 | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Common Stock, Shares Outstanding | 110,259,653 | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Well Known Seasoned Issuer | No | ||
Entity Public Float | $ 42,290,549 | ||
Document Fiscal Year Focus | 2019 | ||
Document Fiscal Period Focus | FY | ||
Entity Shell Company | false | ||
Entity Small Business | false | ||
Entity Emerging Growth Company | false | ||
Entity Interactive Data Current | Yes |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2019 | Dec. 31, 2018 |
Current | ||
Cash | $ 1,332 | $ 6,815 |
Short-term investments | 580 | 4,180 |
Accounts receivable | 381 | 815 |
Prepaid expenses | 170 | 462 |
Investment tax credits receivable | 375 | 416 |
Inventory | 382 | 375 |
Total current assets | 3,220 | 13,063 |
Leasehold improvements and equipment, net | 6,365 | 6,248 |
Security deposits | 752 | 707 |
Operating lease right-of-use-asset | 683 | |
Total assets | 11,020 | 20,018 |
Current | ||
Accounts payable and accrued liabilities | 1,941 | 2,030 |
Current portion of long-term debt | 727 | 692 |
Current portion of operating lease liability | 137 | |
Convertible debentures | 5,642 | |
Total current liabilities | 8,447 | 2,722 |
Deferred lease obligations | 49 | |
Long-term debt | 470 | 1,140 |
Convertible debentures | 5,047 | |
Convertible notes | 1,255 | 1,073 |
Operating lease liability | 555 | |
Total liabilities | 10,727 | 10,031 |
Commitments | ||
Subsequent event | ||
Shareholders' equity | ||
Capital stock, common shares, $0.00001 par value; 200,000,000 shares authorized; 93,942,652 shares issued and outstanding (2018: 93,477,473 common shares) | 1 | 1 |
Additional paid-in capital | 42,635 | 42,048 |
Accumulated deficit | (41,507) | (30,896) |
Accumulated other comprehensive loss | (836) | (1,166) |
Total shareholders' equity | 293 | 9,987 |
Total liabilities and shareholders' equity | $ 11,020 | $ 20,018 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares | Dec. 31, 2019 | Dec. 31, 2018 |
Statement of Financial Position [Abstract] | ||
Common stock, par value per share (in dollars per share) | $ 0.00001 | $ 0.00001 |
Common Stock, Shares Authorized | 200,000,000 | 200,000,000 |
Common Stock, Shares, Issued | 93,942,652 | 93,477,473 |
Common Stock, Shares, Outstanding | 93,942,652 | 93,477,473 |
Consolidated Statement of Share
Consolidated Statement of Shareholders' Equity - USD ($) $ in Thousands | Common Stock [Member] | Additional Paid-In Capital [Member] | Accumulated Deficit [Member] | Accumulated Other Comprehensive Loss [Member] | Total |
Beginning Balance at Dec. 31, 2017 | $ 1 | $ 25,253 | $ (20,788) | $ (637) | $ 3,829 |
Beginning Balance (in shares) at Dec. 31, 2017 | 67,031,467 | ||||
Other comprehensive loss (income) | (529) | (529) | |||
Common stock issued, net of transaction costs of $1,906 | 11,647 | 11,647 | |||
Common stock issued, net of transaction costs of $1,906 (Shares) | 22,017,295 | ||||
Warrants issued, net of transaction costs of $322 | 1,873 | 1,873 | |||
Agents' warrants issued | 330 | 330 | |||
Interest paid by issuance of common shares | 231 | 231 | |||
Interest paid by issuance of common shares (in shares) | 307,069 | ||||
Conversion of convertible debentures | 16 | 16 | |||
Conversion of convertible debentures (in shares) | 17,036 | ||||
Warrants exercised | 2,295 | 2,295 | |||
Warrants exercised (in shares) | 4,044,606 | ||||
Options exercised | 33 | 33 | |||
Options exercised (in shares) | 60,000 | ||||
Stock-based compensation | 370 | 370 | |||
Net loss for the year | (10,108) | (10,108) | |||
Ending Balance at Dec. 31, 2018 | $ 1 | 42,048 | (30,896) | (1,166) | 9,987 |
Ending Balance (in shares) at Dec. 31, 2018 | 93,477,473 | ||||
Modified retrospective adjustment upon adoption of ASC 842 | 49 | 49 | |||
Other comprehensive loss (income) | 330 | 330 | |||
Interest paid by issuance of common shares | 233 | 233 | |||
Interest paid by issuance of common shares (in shares) | 415,179 | ||||
Options exercised | 21 | 21 | |||
Options exercised (in shares) | 50,000 | ||||
Stock-based compensation | 333 | 333 | |||
Net loss for the year | (10,660) | (10,660) | |||
Ending Balance at Dec. 31, 2019 | $ 1 | $ 42,635 | $ (41,507) | $ (836) | $ 293 |
Ending Balance (in shares) at Dec. 31, 2019 | 93,942,652 |
Consolidated Statement of Sha_2
Consolidated Statement of Shareholders' Equity (Parenthetical) $ in Thousands | 12 Months Ended |
Dec. 31, 2018USD ($) | |
Statement of Stockholders' Equity [Abstract] | |
Common stock transaction cost | $ 1,906 |
Warrants transaction cost | $ 322 |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
Revenues | ||
Revenues | $ 742 | $ 1,824 |
Total revenues | 742 | 1,824 |
Expenses | ||
Research and development expense | 3,774 | 5,104 |
Selling, general and administrative expense | 5,800 | 4,999 |
Depreciation of tangible assets | 718 | 719 |
Total expenses | 10,292 | 10,822 |
Operating loss | (9,550) | (8,998) |
Interest income | 97 | 11 |
Financing and interest expense | (1,207) | (1,121) |
Net financing and interest expense | (1,110) | (1,110) |
Loss before income taxes | (10,660) | (10,108) |
Income taxes | 0 | 0 |
Net loss | (10,660) | (10,108) |
Other comprehensive income (loss) | ||
Change in fair value | 46 | 3 |
Foreign currency translation adjustment | 284 | (532) |
Total other comprehensive income (loss) | 330 | (529) |
Comprehensive loss | $ (10,330) | $ (10,637) |
Basic and diluted: | ||
Weighted average number of shares outstanding (in shares) | 93,525,413 | 74,121,922 |
Basic and diluted loss per common share (in dollars per share) | $ (0.11) | $ (0.14) |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
Funds (used) provided - Operating activities | ||
Net loss | $ (10,660) | $ (10,108) |
Depreciation of tangible assets | 718 | 719 |
Stock-based compensation | 333 | 370 |
Accretion expense | 514 | 396 |
DSU expense | 105 | 160 |
Interest paid by issuance of common shares | 228 | 231 |
Lease non-cash expense | 8 | |
Conversion of convertible debentures | (16) | |
Total Adjustment | (8,754) | (8,248) |
Changes in non-cash items related to operations: | ||
Accounts receivable | 426 | (192) |
Prepaid expenses | 292 | (259) |
Investment tax credits receivable | 41 | (102) |
Inventory | (375) | |
Security deposits | (11) | |
Accounts payable and accrued liabilities | (204) | 658 |
Deferred lease obligations | (1) | |
Net change in non-cash items related to operations | 555 | (282) |
Net cash used in operating activities | (8,199) | (8,530) |
Financing activities | ||
Repayment of long-term debt | (711) | (749) |
Proceeds from exercise of warrants and stock options | 21 | 2,328 |
Net proceeds from private placement | 4,004 | |
Transaction costs of private placement | (82) | |
Net proceeds from public offering | 11,405 | |
Transaction costs of public offering | (502) | |
Net cash (used in) provided by financing activities | (690) | 16,404 |
Investing activities | ||
Additions to leasehold improvements and equipment | (525) | (1,096) |
Acquisitions of short-term investments | (1,535) | (4,273) |
Redemptions of short-term investments | 5,265 | 3,192 |
Net cash provided by (used in) investing activities | 3,205 | (2,177) |
(Decrease) Increase in cash | (5,684) | 5,697 |
Effect of foreign exchange on cash | 201 | (473) |
Cash | ||
Beginning of year | 6,815 | 1,591 |
End of year | $ 1,332 | $ 6,815 |
Basis of Presentation
Basis of Presentation | 12 Months Ended |
Dec. 31, 2019 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Basis of Presentation [Text Block] | 1. Basis of Presentation IntelGenx Technologies Corp. ("IntelGenx" or the "Company") prepares its consolidated financial statements in accordance with accounting principles generally accepted in the United States of America ("USA"). This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The consolidated financial statements include the accounts of the Company and its subsidiary companies. On consolidation, all inter-entity transactions and balances have been eliminated. The financial statements are expressed in U.S. funds. |
Going Concern
Going Concern | 12 Months Ended |
Dec. 31, 2019 | |
Going Concern [Abstract] | |
Going Concern [Text Block] | 2. Going Concern The Company has financed its operations to date primarily through public offerings of its common stock, bank loans, royalty, up-front and milestone payments, license fees, proceeds from exercise of warrants and options, research and development revenues and the sale of U.S. royalty on future sales of Forfivo XL ® • Raise funding through the possible sale of the Company's common stock, including public or private equity financings. • Raise funding through debt financing. • Continue to seek partners to advance product pipeline. • Initiate oral film manufacturing activities. • Initiate contract oral film manufacturing activities. On February 11, 2020, the Company announced that it has closed its offering (the "Offering") of 16,317,000 units (the "Units") at a price of CAD$0.50 per Unit (the "Offering Price") for gross proceeds of CAD$8,158,500. If the Company is unable to raise further capital when needed or on attractive terms, or if it is unable to procure partnership arrangements to advance its programs, the Company would be forced to delay, reduce or eliminate its research and development programs. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The accompanying consolidated financial statements do not include any adjustments or classifications that may result from the possible inability of the Company to continue as a going concern. Should the Company be unable to continue as a going concern, it may be unable to realize the carrying value of its assets and to meet its liabilities as they become due. |
Nature of Business
Nature of Business | 12 Months Ended |
Dec. 31, 2019 | |
Nature of Business [Abstract] | |
Nature of Business [Text Block] | 3. Nature of Business IntelGenx was incorporated in the State of Delaware as Big Flash Corp. on July 27, 1999. On April 28, 2006 Big Flash Corp. completed, through the Canadian holding corporation, the acquisition of IntelGenx Corp., a company incorporated in Canada on June 15, 2003 and headquartered in Montreal, Quebec. IntelGenx Corp. has continued operations as our operating subsidiary. IntelGenx Corp. is a drug delivery company focused on the development and manufacturing of novel oral thin film products for the pharmaceutical market. More recently, the Company has made the strategic decision to enter the Canadian cannabis market with a non-prescription cannabis infused oral film. In addition, IntelGenx is offering partners a comprehensive portfolio of pharmaceutical services, including pharmaceutical research and development, clinical monitoring, regulatory support, technology transfer and manufacturing scale-up, and commercial manufacturing. The Company's main product development efforts are based upon three delivery platform technologies: (1) VersaFilm™, an oral film technology, (2) AdVersa®, a mucoadhesive tablet technology and (3) the VetaFilm TM The Company's opportunity assessment and product development strategies primarily focus on addressing unmet market needs and utilize the U.S. Food and Drug Administration's ("FDA") 505(b)(2) approval process to obtain more timely and efficient approval of new formulations of previously approved products. The Company's primary growth strategy is based on three pillars: (1) out licensing commercial rights of existing pipeline products, (2) partnering in contract development and manufacturing projects leveraging its various technology platforms, and (3) expanding its current pipeline. The Company's product pipeline currently consists of 11 products in various stages of development from inception through commercialization, including products for the treatment of Alzheimer's disease, opioid dependence, erectile dysfunction, migraine, schizophrenia, idiopathic pulmonary fibrosis, and pain management. Of the products currently under development, 10 utilize the VersaFilm™ AdVersa™ |
Adoption of New Accounting Stan
Adoption of New Accounting Standards | 12 Months Ended |
Dec. 31, 2019 | |
New Accounting Pronouncements and Changes in Accounting Principles [Abstract] | |
Adoption of New Accounting Standards [Tex Block] | 4. Adoption of New Accounting Standards The Company adopted Topic 842 Leases with a date of the initial application of January 1, 2019. As a result, the Company has changed its accounting policy for leases as detailed below. The Company adopted Topic 842 using a modified retrospective approach with a date of initial application of January 1, 2019, which requires the recognition of the right-of-use assets and related operating and finance lease liabilities on the balance sheet. As a result, the consolidated balance sheet prior to January 1, 2019 was not restated, continues to be reported under ASC Topic 840, Leases, or ASC 840, which did not require the recognition of operating lease liabilities on the balance sheet, and is not comparative. Under ASC 842, all leases are required to be recorded on the balance sheet and are classified as either operating or finance leases. The lease classification affects the expense recognition in the income statement. Operating lease charges are recorded entirely in selling, general and administrative expense. Finance lease charges are split, where amortization of the right-of-use asset is recorded in selling, general and administrative expense and an implied interest component is recorded in financing and interest expense. At the moment of initial application, the Company did not hold any finance leases. The expense recognition for operating leases under ASC 842 is substantially consistent with ASC 840. As a result, there is no significant difference in our results of operations presented in our consolidated income statement and consolidated statement of comprehensive loss for each period presented. The adoption of ASC 842 had a substantial impact on the Company's balance sheet. The most significant impact was the recognition of the operating lease right-of-use asset and operating lease liability. Upon adoption, leases that were classified as operating leases under ASC 840 were classified as operating leases under ASC 842, and the Company recorded an adjustment of $726 to operating lease right-of-use asset and the related operating lease liability. The operating lease liability is based on the present value of the remaining minimum lease payments, determined under ASC 840, discounted using our secured incremental borrowing rate at the effective date of January 1, 2019, using the original lease term and the tenor. As permitted under ASC 842, the Company elected to use the practical expedient that permits to use hindsight in determining the lease term. The application of the practical expedients did not have a significant impact on the measurement of the operating lease liability. The impact of the adoption of ASC 842 on the balance sheet as at December 31, 2018 was: As reported December 31, 2018 Adoption of ASC 842 Increase (Decrease) Balance January 1, 2019 Operating lease right-of-use assets $ — $ 726 $ 726 Total assets 20,018 726 20,744 Total current liabilities 2,722 127 2,849 Deferred lease obligations 49 (49 ) — Operating lease liability — 599 599 Total liabilities 10,031 677 10,708 Total shareholders' equity 9,987 49 10,036 Total liabilities and shareholders' equity 20,018 726 20,744 The FASB issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees. These amendments are effective for a public business entity for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The adoption of this statement did not have a material effect on the Company's financial position of results. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2019 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies [Text Block] | 5. Summary of Significant Accounting Policies Revenue Recognition The Company may enter into licensing and collaboration agreements for product development, licensing, supply and manufacturing for its product pipeline. The terms of the agreements may include non-refundable signing and licensing fees, milestone payments and royalties on any product sales derived from collaborations. These contracts are analyzed to identify all performance obligations forming part of these contracts. The transaction price of the contract is then determined. The transaction price is allocated between all performance obligations on a residual standalone selling price basis. The stand-alone selling price is estimated based on the comparable market prices, expected cost plus margin and the Company's historical experience. Revenue is measured based on a consideration specified in a contract with a customer, and excludes any sales incentives and amounts collected on behalf of third parties. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a product or service to a customer. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. The following is a description of principal activities - separated by nature - from which the Company generates its revenue. Research and Development Revenue Revenues with corporate collaborators are recognized as the performance obligations are satisfied over time, and the related expenditures are incurred pursuant to the terms of the agreement. Licensing and Collaboration Arrangements Licenses are considered to be right-to-use licenses. As such, the Company recognizes the licenses revenues at a point in time, upon granting the licenses. Milestone payments are considered variable consideration. As such, the Company estimates variable consideration at the most likely amount to which we expect to be entitled. The estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, research and other revenues in the period during which the adjustment is recognized. The process of successfully achieving the criteria for the milestone payments is highly uncertain. Consequently, there is significant risk that the Company may not earn all of the milestone payments for each of its contracts. Royalties are typically calculated as a percentage of net sales realized by the Company's licensees of its products (including their sub-licensees), as specifically defined in each agreement. The licensees' sales generally consist of revenues from product sales of the Company's product pipeline and net sales are determined by deducting the following: estimates for chargebacks, rebates, sales incentives and allowances, returns and losses and other customary deductions in each region where the Company has licensees. Revenues arising from royalties are considered variable consideration. As such, the Company estimates variable consideration at the most likely amount to which we expect to be entitled. The estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The financial statements include estimates based on currently available information and management's judgment as to the outcome of future conditions and circumstances. Significant estimates in these financial statements include the useful lives and impairment of long-lived assets, stock-based compensation costs, and the investment tax credits receivable. Changes in the status of certain facts or circumstances could result in material changes to the estimates used in the preparation of the financial statements and actual results could differ from the estimates and assumptions. Accounts Receivable The Company accounts for trade receivables at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a quarterly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer's financial condition, credit history and current economic conditions. The Company writes off trade receivables when they are deemed uncollectible and records recoveries of trade receivables previously written off when they receive them. Management has determined that no allowance for doubtful accounts is necessary in order to adequately cover exposure to loss in its December 31, 2019 accounts receivable (2018: $). A bad debt expense in the amount of $ (2018: $) is recorded in the year ended December 31, 2019. Investment Tax Credits Investment tax credits relating to qualifying expenditures are recognized in the accounts at the time at which the related expenditures are incurred and there is reasonable assurance of their realization. Management has made estimates and assumptions in determining the expenditures eligible for investment tax credits claimed. Investment tax credits received in the year ended December 31, 2019 totaled $416 thousand (2018: $289). Inventory The Company values inventory at the lower of cost and net realizable value where net realizable value represents the expected sale price upon disposition less make-ready costs and the costs of disposal and transportation and determines the cost of raw material inventory using the average-cost method. The Company analyzes its inventory levels quarterly and adjusts inventory to its net realizable value, if required, for obsolete, or has a cost basis in excess of its expected net realizable value. Leasehold Improvements and Equipment Leasehold improvements and equipment are recorded at cost. Provisions for depreciation are based on their estimated useful lives using the methods as follows: On the declining balance method - Laboratory and office equipment 20% Computer equipment 30% On the straight-line method - Leasehold improvements over the lease term Manufacturing equipment 5 - 10 years Upon retirement or disposal, the cost of the asset disposed of and the related accumulated depreciation are removed from the accounts and any gain or loss is reflected in income. Expenditures for repair and maintenance are expensed as incurred. Leases Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: the lease transfers ownership of the asset by the end of the lease term, the lease contains an option to purchase the asset that is reasonably certain to be exercised, the lease term is for a major part of the remaining useful life of the asset or the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it does not meet any one of these criteria. Substantially all of the Company's operating leases are comprised of office space and property leases and the Company does not hold any finance leases. For all leases at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial costs incurred, consisting mainly of brokerage commissions, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's secured incremental borrowing rate for the same term as the underlying lease. Lease payments included in the measurement of the lease liability comprise the following: the fixed noncancelable lease payments, payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, and payments for early termination options unless it is reasonably certain the lease will not be terminated early. Lease modifications result in remeasurement of the lease liability. Lease expense for operating leases consists of the lease payments plus any initial direct costs, primarily brokerage commissions, and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability. The Company has elected not to recognize right-of-use assets and lease liabilities for short-tern leases that have a term of 12 months or less. The effect of short-term leases on our right-of-use asset and lease liability was not material. Security Deposits Security deposits represent a refundable deposit paid to the landlord in accordance with the lease agreement and deposits held as guarantees by the Company's lenders in accordance with the lending facilities. The deposits will be repaid to the Company at the end of the lease. Impairment of Long-lived Assets Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the estimated undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value there of. Foreign Currency Translation The Company's reporting currency is the U.S. dollar. The Canadian dollar is the functional currency of the Company's Canadian operations, which is translated to the United States dollar using the current rate method. Under this method, accounts are translated as follows: Gains and losses arising from foreign currency translation are included in other comprehensive income. Income Taxes The Company accounts for income taxes in accordance with FASB ASC 740 "Income Taxes". Deferred taxes are provided on the liability method whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Unrecognized Tax Benefits The Company accounts for unrecognized tax benefits in accordance with FASB ASC 740 "Income Taxes". ASC 740 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. ASC 740 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon ultimate settlement with a taxing authority, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. Additionally, ASC 740 requires the Company to accrue interest and related penalties, if applicable, on all tax positions for which reserves have been established consistent with jurisdictional tax laws. The Company elected to classify interest and penalties related to the unrecognized tax benefits in the income tax provision. Share-Based Payments The Company accounts for share-based payments to employees in accordance with the provisions of FASB ASC 718 "Compensation-Stock Compensation" and accordingly recognizes in its financial statements share-based payments at their fair value. In addition, the Company will recognize in the financial statements an expense based on the grant date fair value of stock options granted to employees. The expense will be recognized on a straight-line basis over the vesting period and the offsetting credit will be recorded in additional paid-in capital. Upon exercise of options, the consideration paid together with the amount previously recorded as additional paid-in capital will be recognized as capital stock. The Company uses the Black-Scholes option pricing model to determine the fair value of the options. The Company measures compensation expense for its non-employee stock-based compensation under ASC 718, "Compensation-Stock Compensation" and accordingly recognizes in its financial statements share-based payments at their fair value. In addition, the Company will recognize in the financial statements as expense over the service period, as if the Company had paid cash for the services. Loss Per Share Basic loss per share is calculated based on the weighted average number of shares outstanding during the year. Any antidilutive instruments are excluded from the calculation of diluted loss per share. Fair Value Measurements ASC 820 applies to all assets and liabilities that are being measured and reported on a fair value basis. ASC 820 requires disclosure that establishes a framework for measuring fair value in US GAAP, and expands disclosure about fair value measurements. This statement enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The statement requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories: Level 1: Level 2: Level 3: In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are subject to ASC 820. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. Short-term investments are classified Level 1. Fair Value of Financial Instruments The fair value represents management's best estimates based on a range of methodologies and assumptions. The carrying value of receivables and payables arising in the ordinary course of business and the investment tax credits receivable approximate fair value because of the relatively short period of time between their origination and expected realization. Recent Accounting Pronouncements ASU 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes The FASB issued ASU 2019-12 which removes specific exceptions to the general principles in Topic 740 in Generally Accepted Accounting Principles (GAAP). It eliminates the need for an organization to analyze whether the following apply in a given period: -Exception to the incremental approach for intraperiod tax allocation; -Exceptions to accounting for basis differences when there are ownership changes in foreign investments; and -Exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses. The ASU also improves financial statement preparers' application of income tax-related guidance and simplifies GAAP for: -Franchise taxes that are partially based on income; -Transactions with a government that result in a step up in the tax basis of goodwill; -Separate financial statements of legal entities that are not subject to tax; and -Enacted changes in tax laws in interim periods. These amendments are effective for fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. ASU 2019-11 Codification Improvements to Topic 326, Financial Instruments - Credit Losses The FASB issued ASU 2019-11 which clarifies guidance around how to report expected recoveries. "Expected recoveries" describes a situation in which an organization recognizes a full or partial writeoff of the amortized cost basis of a financial asset, but then later determines that the amount written off, or a portion of that amount, will in fact be recovered. This ASU permits organizations to record expected recoveries on PCD assets. These amendments are effective for fiscal years beginning after December 15, 2019. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. ASU 2019-08 Compensation - Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Codification Improvements - Share-Based Consideration Payable to a Customer The FASB issued ASU 2019-08 which requires companies to measure and classify (on the balance sheet) share-based payments to customers by applying the guidance in Topic 718, Compensation-Stock Compensation. As a result, the amount recorded as a reduction in revenue would be measured based on the grant-date fair value of the share-based payment. These amendments are effective for fiscal years beginning after December 15, 2019. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. ASU 2019-05 Credit Losses (Topic 326): Targeted Transition Relief The FASB issued ASU 2019-05 which provides entities that have certain instruments within the scope of Subtopic 326-20, Financial Instruments - Credit Losses - Measured at Amortized Cost, with an option to irrevocably elect the fair value option in Subtopic 825-10, Financial Instruments - Overall, applied on an instrument-by-instrument basis for eligible instruments, upon adoption of Topic 326. The fair value option election does not apply to held-to-maturity debt securities. An entity that elects the fair value option should subsequently apply the guidance in Subtopics 820-10, Fair Value Measurement - Overall, and 825-10. These amendments are effective for fiscal years beginning after December 15, 2019. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. ASU 2018-19 Codification Improvements to Topic 326, Financial Instruments-Credit Losses The FASB issued ASU 2018-19 which mitigates transition complexity by requiring entities other than public business entities, including not-for-profit organizations and certain employee benefit plans, to implement the credit losses standard issued in 2016, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. This aligns the implementation date for their annual financial statements with the implementation date for their interim financial statements. The guidance also clarifies that receivables arising from operating leases are not within the scope of the credit losses standard, but rather, should be accounted for in accordance with the leases standard. These amendments are effective for fiscal years beginning after December 15, 2019. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. ASU 2018-18 Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606 The FASB issued ASU 2018-18 which provides guidance on how to assess whether certain transactions between collaborative arrangement participants should be accounted for within the revenue recognition standard. The ASU also provides more comparability in the presentation of revenue for certain transactions between collaborative arrangement participants. It accomplishes this by allowing organizations to only present units of account in collaborative arrangements that are within the scope of the revenue recognition standard together with revenue accounted for under the revenue recognition standard. The parts of the collaborative arrangement that are not in the scope of the revenue recognition standard should be presented separately from revenue accounted for under the revenue recognition standard. These amendments are effective for fiscal years beginning after December 15, 2019. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. ASU 2018-13 - Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement The FASB issued ASU 2018-13 which modifies the disclosure requirements in Topic 820 as follows: Removals -The amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; -The policy for timing of transfers between levels; -The valuation processes for Level 3 fair value measurements; and -For nonpublic entities, the changes in unrealized gains and losses for the period included in earnings for recurring Level 3 fair value measurements held at the end of the reporting period. Modifications -In lieu of a rollforward for Level 3 fair value measurements, a nonpublic entity is required to disclose transfers into and out of Level 3 of the fair value hierarchy and purchases and issues of Level 3 assets and liabilities; -For investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee's assets and the date when restrictions from redemption might lapse only if the investee has communicated the timing to the entity or announced the timing publicly; and -The amendments clarify that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date Additions -The changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period; and - The range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. For certain unobservable inputs, an entity may disclose other quantitative information (such as the median or arithmetic average) in lieu of the weighted average if the entity determines that other quantitative information would be a more reasonable and rational method to reflect the distribution of unobservable inputs used to develop Level 3 fair value measurements. These amendments are effective for fiscal years beginning after December 15, 2019. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. |
Short-term investments
Short-term investments | 12 Months Ended |
Dec. 31, 2019 | |
Cash and Cash Equivalents [Abstract] | |
Short-term investments [Text Block] | 6. Short-term investments |
Inventory
Inventory | 12 Months Ended |
Dec. 31, 2019 | |
Inventory Disclosure [Abstract] | |
Inventory | 7. Inventory Inventory as at December 31, 2019 consisted of raw materials in the amount of $382 thousand (2018 - $375 thousand). |
Leasehold Improvements and Equi
Leasehold Improvements and Equipment | 12 Months Ended |
Dec. 31, 2019 | |
Property, Plant and Equipment [Abstract] | |
Leasehold improvements and Equipment [Text Block] | 8. Leasehold improvements and Equipment 2019 2018 Accumulated Net Carrying Net Carrying Cost Depreciation Amount Amount Manufacturing equipment $ 4,657 $ 879 $ 3,778 $ 3,512 Laboratory and office equipment 1,368 870 498 562 Computer equipment 125 85 40 39 Leasehold improvements 3,325 1,276 2,049 2,135 $ 9,475 $ 3,110 $ 6,365 $ 6,248 From the balance of manufacturing equipment, an amount of $1,788 thousand (2018 - $1,703 thousand) represents assets which are still under construction as at December 31, 2019 and are consequently not depreciated. The commitment of the Company for the remainder of the project is as disclosed in note 13. |
Bank indebtedness
Bank indebtedness | 12 Months Ended |
Dec. 31, 2019 | |
Bank Indebtedness [Abstract] | |
Bank indebtedness [Text Block] | 9. Bank Indebtedness The Company's credit facility is subject to review annually and consists of an operating demand line of credit of up to CAD$250 thousand ($192 thousand) CAD$75 thousand ($58 thousand), CAD$425 thousand ($327 thousand). Borrowings under the operating demand line of credit bear interest at the Bank's prime lending rate plus 2%. The credit facility and term loan (see note 10) are secured by a first ranking movable hypothec on all present and future movable property of the Company for an amount of CAD$4,250,000 ($3,272,000) plus 20%, and a 50% guarantee by Export Development Canada, a Canadian Crown corporation export credit agency. |
Long-term debt
Long-term debt | 12 Months Ended |
Dec. 31, 2019 | |
Other Liabilities Disclosure [Abstract] | |
Long-term debt [Text Block] | 10. Long-term debt The components of the Company’s debt are as follows: December 31, 2019 December 31, 2018 $ $ Term loan facility 1,005 1,502 Secured loan 192 330 Total debt 1,197 1,832 Less: current portion 727 692 Total long-term debt 470 1,140 The Company’s term loan facility consists of a total of CAD$4 million ($3.08 million) bearing interest at the Bank’s prime lending rate plus 2.50%, with monthly principal repayments of CAD$62 thousand ($48 thousand). The term loan is subject to the same security and financial covenants as the bank indebtedness (see note 9). The secured loan has a principal balance authorized of CAD$1 million ($770 thousand) bearing interest at prime plus 7.3%, reimbursable in monthly principal payments of CAD$17 thousand ($13 thousand). The loan is secured by a second ranking on all present and future property of the Company. The terms of the banking agreement require the Company to comply with certain debt service coverage and debt to net worth financial covenants on an annual basis at the end of the Company’s fiscal year. As at December 31, 2019, the Company was not in compliance with its financial covenants. The Company has obtained a waiver from the lender. Principal repayments due in each of the next two years are as follows: 2020 727 (CAD 945) 2021 470 (CAD 610) |
Convertible Debentures
Convertible Debentures | 12 Months Ended |
Dec. 31, 2019 | |
Convertible Debt [Abstract] | |
Convertible Debentures [Text Block] | 11. Convertible Debentures On July 12, 2017, the Company closed its previously announced prospectus offering (the "Offering") of convertible unsecured subordinated debentures of the Corporation (the "Debentures") for gross aggregate proceeds of CAD$6,838,000 ($5,265,000). Pursuant to the Offering, the Corporation issued an aggregate principal amount of CAD$6,838,000 ($ ) of Debentures at a price of CAD$1,000 ($770) per Debenture. The Debentures will mature on June 30, 2020 and bear interest at annual rate of 8% payable semi-annually on the last day of June and December of each year, commencing on December 31, 2017. The interest may be paid in common shares at the option of the Corporation. The Debentures will be convertible at the option of the holders at any time prior to the close of business on the earlier of June 30, 2020 and the business day immediately preceding the date specified by the Corporation for redemption of Debentures. The conversion price will be CAD$1.35 ($1.04) (the "Conversion Price") per common share of the Corporation ("Share"), being a conversion rate of approximately 740 Shares per CAD$1,000 ($770) principal amount of Debentures, subject to adjustment in certain events. On August 8, 2017, the Company closed a second tranche of its prospectus Offering of convertible unsecured subordinated debentures of the Corporation for which a first closing took place on July 12, pursuant to which it had raised additional gross proceeds of CAD$762,000 ($587,000). Together with the principal amount of CAD$6,838,000 ($5,265,000) of Debentures issued on July 12, 2017, the Corporation issued a total aggregate principal amount of CAD$7,600,000 of Debentures at a price of CAD$1,000 ($770) per Debenture. The convertible debentures have been recorded as a liability. Total transactions costs in the amount of CAD$1,237,000 ($952,000) were recorded against the liability. The accretion expense for the year ended December 31, 2019 amounts to CAD$443,000 ($334,000) compared to CAD$383,000 ($296,000) for the year ended December 31, 2018. During the year ended December 31, 2018, CAD$23,000 ($17,000) of convertible debentures were converted into 17,036 common shares at the option of the holders, resulting in an increase in additional paid-in capital of $16 thousand. The components of the convertible debentures are as follows: December 31, December 31, 2019 2018 Face value of the convertible debentures $ 5,835 $ 5,556 Transaction costs (952 ) (907 ) Accretion 759 398 Convertible debentures $ 5,642 $ 5,047 Interest accrued during the year ended December 31, 2019 on the convertible debentures amounts to CAD$606 thousand ($457 thousand) out of which and CAD$303 thousand ($229 thousand) was paid in cash on June 27, 2019 and CAD$303 thousand ($228 thousand) was paid by issuance of 415,179 common shares on December 31, 2019 Interest accrued during the year ended December 31, 2018 on the convertible debentures amounts to CAD$607 thousand ($468 thousand) out of which CAD$304 thousand ($231 thousand) was paid by issuance of 307,069 common shares on July 3, 2018 and CAD$303 thousand ($237 thousand) was paid in cash on December 28, 2018. |
Convertible Note
Convertible Note | 12 Months Ended |
Dec. 31, 2019 | |
Convertible Notes [Abstract] | |
Convertible Notes [Text Block] | 12. Convertible Notes On May 8, 2018, the Company closed its previously announced offering by way of private placement (the “Offering”). In connection with the Offering, the Company issued 320 units (the “Units”) at a subscription price of $10,000 per Unit for gross proceeds of $3,200,000. A related party of the Company participated in the Offering and subscribed for an aggregate of two Units. Each Unit is comprised of (i) 7,940 common shares of the Corporation (“Common Shares”), (ii) a $5,000 convertible 6% note (a “Note”), and (iii) 7,690 warrants to purchase common shares of the Corporation (“Warrants”). Each Note bears interest at a rate of 6% (payable quarterly, in arrears, with the first payment being due on September 1, 2018), matures on June 1, 2021 and is convertible into Common Shares at a conversion price of $0.80 per Common Share. Each Warrant entitles its holder to purchase one Common Share at a price of $0.80 per Common Share until June 1, 2021. In connection with the Offering, the Company paid to the Agents a cash commission of approximately $157,800 in the aggregate and issued non-transferable agents’ warrants to the Agents, entitling the Agents to purchase 243,275 common shares at a price of $0.80 per share until June 1, 2021. Management has determined the value of the agents’ warrants to be $50,000. The proceeds of the Units are attributed to liability and equity components based on the fair value of each component as follows: Gross proceeds Transaction costs Net proceeds Common stock $ 1,627 $ 167 $ 1,460 Convertible notes 1,086 111 975 Warrants 487 50 437 $ 3,200 $ 328 $ 2,872 The convertible notes have been recorded as a liability. Total transactions costs in the amount of $111 thousand were recorded against the liability. The components of the convertible notes are as follows: December 31, December 31, 2019 2018 Attributed value of net proceeds to convertible notes $ 975 975 Accretion 280 98 Convertible notes $ 1,255 1,073 The interest on the convertible notes for the year ended December 31, 2019 amounts to $96,000 (2018: $63,000) and is recorded in financing and interest expense. The proceeds of the Units are attributed to liability and equity components based on the fair value of each component. Management has determined the value attributed to the common stock is $1,460 and $437 for the warrants issued, resulting in an increase in additional paid-in-capital of $1,897. |
Commitments
Commitments | 12 Months Ended |
Dec. 31, 2019 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments [Text Block] | 13. Commitments The Company has initiated a project to expand the existing manufacturing facility. The Company has signed agreements in the amount of Euro1,911 thousand with three suppliers with respect to equipment for solvent film manufacturing. As at December 31, 2019 an amount of Euro1,425 thousand has been paid with respect to these agreements (note 8). |
Capital Stock
Capital Stock | 12 Months Ended |
Dec. 31, 2019 | |
Stockholders' Equity Note [Abstract] | |
Capital Stock [Text Block] | 14. Capital Stock 2019 2018 Authorized - 200,000,000 common shares of $0.00001 par value 20,000,000 preferred shares of $0.00001 par value Issued - 93,942,652 (December 31, 2018: 93,477,473) common shares $ 1 $ 1 Private placement On May 8, 2018, the Company closed its previously announced offering by way of private placement (the "Offering"). In connection with the Offering, the Company issued 320 units (the "Units") at a subscription price of $10,000 per Unit for gross proceeds of $3,200,000. A related party of the Company participated in the Offering and subscribed for an aggregate of two Units. Each Unit is comprised of (i) 7,940 common shares of the Corporation ("Common Shares"), (ii) a $5,000 convertible 6% note (a “Note”), and (iii) 7,690 warrants to purchase common shares of the Corporation (“Warrants”). Each Note bears interest at a rate of 6% (payable quarterly, in arrears, with the first payment being due on September 1, 2018), matures on June 1, 2021 and is convertible into Common Shares at a conversion price of $0.80 per Common Share. Each Warrant entitles its holder to purchase one Common Share at a price of $0.80 per Common Share until June 1, 2021. In connection with the Offering, the Company paid to the Agents a cash commission of approximately $157,800 in the aggregate and issued non-transferable agents’ warrants to the Agents, entitling the Agents to purchase 243,275 common shares at a price of $0.80 per share until June 1, 2021. Management has determined the value of the agents’ warrants to be $50,000, resulting in an increase in additional paid-in-capital of $50 thousand. The proceeds of the Units are attributed to liability and equity components based on the fair value of each component, resulting in an increase in additional paid-in-capital of $1,897. Management has determined the value attributed to common stock is $1,460 and $437 for the warrants issued. Private Placement Financing On November 13, 2018, the Company announced the closing of Tilray Inc.’s strategic investment in IntelGenx by way of a private placement. Pursuant to the private placement, the Company issued 1,428,571 common shares at a subscription price of $0.70 per common share for gross proceeds of $1,000,000, resulting in an increase in additional paid-in capital of $1,000,000. Public Offering On October 22, 2018, IntelGenx announced the closing of 17,144,314 units at a price of US$0.70 for gross proceeds of approximately US$12 million in the United States and the Canadian provinces of Alberta, British Columbia, Manitoba, Ontario and Quebec. On October 26, 2018 IntelGenx announced that Echelon Wealth Partners Inc., who acted as the Company’s exclusive placement agent in Canada in connection with the Offering, had exercised its option to place a further 903,610 Units pursuant to its over-allotment option, resulting in additional gross proceeds to the Company of US$632,527. Each Unit will consist of one share of common stock of the Company and one half of one warrant, each whole Warrant to purchase one share of common stock of the Company at an exercise price of US$1.00 per share. The Warrants are exercisable immediately and will expire on the third anniversary of the date of their issuance. Management has determined the value attributed to common stock is $9,187 and $1,436 for the warrants issued, resulting in an increase in additional paid-in-capital of $10,623. In connection with the Offering, the Company paid to the Agents a cash commission of approximately $560,000 in the aggregate and issued non-transferable agents’ warrants to the Agents, entitling the Agents to purchase 1,226,360 common shares at a price of $0.875 per share until June 1, 2021. Management has determined the value of the agents’ warrants to be $280,000, resulting in an increase in additional paid-in-capital of $280 thousand. The proceeds of the Units are attributed to equity components based on the fair value of each component as follows: Gross proceeds Transaction costs Net proceeds Common stock $ 10,926 $ 1,739 $ 9,187 Warrants 1,708 272 1,436 $ 12,634 $ 2,011 $ 10,623 Stock options During the year ended December 31, 2019 a total of 50,000 stock options were exercised for 50,000 common shares having a par value of $0 thousand in aggregate, for cash consideration of $21 thousand, resulting in an increase in additional paid-in capital of $21 thousand. During the year ended December 31, 2018 a total of 60,000 stock options were exercised for 60,000 common shares having a par value of $0 thousand in aggregate, for cash consideration of $33 thousand, resulting in an increase in additional paid-in capital of $33 thousand. Stock-based compensation of $333 thousand and $370 thousand was recorded during the year ended December 31, 2019 and 2018 respectively. An amount of $286 thousand (2018 - $356 thousand) expensed relates to stock options granted to employees and directors and an amount of $47 thousand (2018- $14 thousand) relates to stock options granted to consultants during the year ended December 31, 2018. As at December 31, 2019 the Company has $157 thousand (2018 - $453 thousand) of unrecognized stock-based compensation, of which $36 thousand (2018 – $83) relates to options granted to consultants. Warrants In the year ended December 31, 2018 a total of 4,044,606 warrants were exercised for 4,044,606 common shares having a par value of $ Nil in aggregate, for cash consideration of approximately $2,295 thousand, resulting in an increase in additional paid-in capital of approximately $2,295 thousand. No warrants were exercised in 2019. |
Additional Paid-In Capital
Additional Paid-In Capital | 12 Months Ended |
Dec. 31, 2019 | |
Additional Paid in Capital [Abstract] | |
Additional Paid-In Capital [Text Block] | 15. Additional Paid-In Capital Stock Options On May 9, 2016, the Board of Directors of the Company adopted the 2016 Stock Option Plan which amended and restated the 2006 Stock Option. As a result of the adoption of the 2016 Stock Option Plan, no additional options will be granted under the 2006 Stock Option Plan and all previously granted options will be governed by the 2016 Stock Option Plan. The 2016 Stock Option Plan permits the granting of options to officers, employees, directors and eligible consultants of the Company. A total of 9,347,747 shares of common stock were reserved for issuance under this plan, which includes stock options granted under the previous 2006 Stock Option Plan. Options may be granted under the 2016 Stock Option Plan on terms and at prices as determined by the Board except that the options cannot be granted at less than the market closing price of the common stock on the TSX- V. on the date prior to the grant. Each option will be exercisable after the period or periods specified in the option agreement, but no option may be exercised after the expiration of 10 years from the date of grant. The 2016 Stock Option Plan provides the Board with more flexibility when setting the vesting schedule for options which was otherwise fixed in the 2006 Stock Option Plan. The fair value of options granted has been estimated according to the Black-Scholes valuation model and based on the weighted average of the following assumptions for options granted to employees and directors during the years ended: 2019 2018 Exercise price 0.69 0.74 Expected volatility 64% 5.9% Expected life 5.63 years 5.63 years Risk‑free interest rate 2.18% 2.73% Dividend yield Nil Nil The weighted average fair value of the options granted to employees during the year ended December 31, 2019 is $0.40 (2018 - $0.40) . The weighted average fair value of the options granted to consultants during the year ended December 31, 2018 is $0.19. No options were granted to consultants during the year ended December 31, 2019. Information with respect to employees and directors stock option activity for 2018 and 2019 is as follows: Weighted average Number of options exercise price Outstanding – January 1, 2018 2,939,818 0.65 Granted 1,250,000 0.74 Forfeited (175,000 ) (0.69 ) Expired (100,000 ) (0.52 ) Exercised (60,000 ) (0.56 ) Outstanding – December 31, 2018 3,854,818 0.68 Granted 100,000 0.69 Forfeited (37,500 ) (0.66 ) Expired (402,500 ) (0.67 ) Exercised (50,000 ) (0.41 ) Outstanding – December 31, 2019 3,464,818 0.68 Information with respect to consultant's stock option activity for 2018 and 2019 is as follows: Weighted average Number of options exercise price $ Outstanding – January 1, 2018 50,000 0.73 Granted 500,000 0.72 Outstanding – December 31, 550,000 0.72 Details of stock options outstanding as at December 31, 2019 are as follows: Outstanding options Exercisable options Weighted Weighted Weighted average average Aggregate average Aggregate Exercise Number of remaining exercise intrinsic Number of exercise intrinsic prices options contractual life price value options price value $ (years) $ $ $ $ 0.41 275,000 0.07 0.03 275,000 0.03 0.58 675,000 0.09 0.10 675,000 0.12 0.62 150,000 0.01 0.02 150,000 0.03 0.66 200,000 0.41 0.03 150,000 0.03 0.69 100,000 0.23 0.02 25,000 0.01 0.70 475,000 0.35 0.08 237,500 0.05 0.73 525,000 0.82 0.10 525,000 0.11 0.76 905,000 1.87 0.17 705,000 0.16 0.77 359,818 0.69 0.07 359,818 0.08 0.78 100,000 0.04 0.02 50,000 0.01 0.89 250,000 0.44 0.06 250,000 0.07 4,014,818 5.02 0.70 16,500 3,402,318 0.70 16,500 Stock-based compensation expense recognized in 2019 with regards to the stock options was $333 thousand (2018: $345 thousand). As at December 31, 2019 the Company has $157 thousand (2018 - $453 thousand) of unrecognized stock-based compensation, of which $36 thousand (2018 – $83 thousand) relates to options granted to consultants. The amount of $157 thousand will be recognized as an expense over a period of two years. A change in control of the Company due to acquisition would cause the vesting of the stock options granted to employees and directors to accelerate and would result in $157 thousand being charged to stock-based compensation expense. Warrants In the year ended December 31, 2018 a total of 4,044,606 warrants were exercised for 4,044,606 common shares having a par value of $ Nil in aggregate, for cash consideration of approximately $2,295 thousand, resulting in an increase in additional paid-in capital of approximately $2,295 thousand. No warrants were exercised in 2019. Information with respect to warrant activity for 2018 and 2019 is as follows: Number of Weighted average warrants exercise price (All Exercisable) $ Outstanding - January 1, 2018 4,070,902 0.5646 Granted 12,954,397 0.9464 Exercised (4,044,606 ) (0.5675 ) Expired (76,296 ) (0.5646 ) Outstanding - 12,904,397 0.9470 Deferred Share Units ("DSUs") Effective February 7, 2018, the Board approved a Deferred Share Unit Plan (DSU Plan) to compensate non-employee directors as part of their annual remuneration. Under the DSU Plan, the Board may grant Deferred Share Units ("DSUs") to the participating directors at its discretion and, in addition, each participating director may elect to receive all or a portion of his or her annual cash stipend in the form of DSUs. To the extent DSUs are granted, the amount of compensation that is deferred is converted into a number of DSUs, as determined by the market price of our Common Stock on the effective date of the election. These DSUs are converted back into a cash amount at the expiration of the deferral period based on the market price of our Common Stock on the expiration date and paid to the director in cash in accordance with the payout terms of the DSU Plan. As the DSUs are on a cash-only basis, no shares of Common Stock will be reserved or issued in connection with the DSUs. On March 27, 2019, 271,740 DSUs (287,355 on May 16, 2018) have been granted under the DSU Plan, accordingly, an amount of $128 thousand ($160 thousand in 2018) has been recognized in general and administrative expenses. Performance and Restricted Share Units ("PRSUs") At the Annual Meeting on May 8, 2018, the shareholders approved the IntelGenx Technologies Corp. Performance and Restricted Share Unit Plan (PRSU Plan) which the Board of Directors had approved on March 19, 2018. The primary purpose of this PRSU Plan is to provide the Company with a share-related mechanism to attract, retain and motivate qualified executive officers of the Company and its Subsidiaries and to reward such executive officers for their contributions toward the long-term goals and success of the Company and to enable and encourage such executive officers to acquire shares of Common Stock as long-term investments and proprietary interests in the Company. As at December 31, 2018, 53,846 rewards have been issued under the PRSU Plan, accordingly an amount of $25 thousand has been recognized as stock-based compensation in general and administrative expenses in 2018. No rewards were granted under the PRSU Plan in 2019. |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2019 | |
Income Tax Disclosure [Abstract] | |
Income Taxes [Text Block] | 16. Income Taxes Income taxes reported differ from the amount computed by applying the statutory rates to net income (losses). The reasons are as follows: 2019 2018 Statutory income taxes $ (2,398 ) $ (2,421 ) Net operating losses for which no tax benefits have been recorded 1,189 1,185 Deficiency of depreciation over capital cost allowance (178 ) (236 ) Non-deductible expenses 667 422 Undeducted research and development expenses 820 1,167 Investment tax credit (100 ) (117 ) $ — $ — The major components of the deferred tax assets classified by the source of temporary differences are as follows: 2019 2018 Leasehold improvements and equipment $ 440 $ 418 Net operating losses carryforward 6,396 4,170 Undeducted research and development expenses 2,903 2,774 Non-refundable tax credits carryforward 2,082 1,982 11,821 9,344 Valuation allowance (11,821 ) (9,344 ) $ — $ — As at December 31, 2019, management determined that enough uncertainty existed relative to the realization of deferred income tax asset balances to warrant the application of a full valuation allowance. Management continues to believe that enough uncertainty exists relative to the realization of the remaining deferred income tax asset balances such that no recognition of deferred income tax assets is warranted. There were Canadian and provincial net operating losses of approximately $23,101 thousand (2018: $14,934 thousand) and $25,264 thousand (2018: $16,498 thousand) respectively, that may be applied against earnings of future years. Utilization of the net operating losses is subject to significant limitations imposed by the change in control provisions. Canadian and provincial losses will be expiring between 2026 and 2039. A portion of the net operating losses may expire before they can be utilized. As at December 31, 2019, the Company had non-refundable tax credits of $2,486 thousand (2018: $1,981 thousand) of which $8 thousand is expiring in 2026, $10 thousand is expiring in 2027, $174 thousand is expiring in 2028, $152 thousand is expiring in 2029, $130 thousand is expiring in 2030, $138 thousand is expiring in 2031, $173 thousand is expiring in 2032, $115 thousand is expiring in 2033, $87 thousand expiring in 2034, $102 thousand is expiring in 2035, $141 thousand expiring in 2036, $270 thousand is expiring in 2037, $582 thousand expiring in 2038 and $404 thousand expiring in 2039 and undeducted research and development expenses of $14,282 thousand (2018: $10,663 thousand) with no expiration date. The deferred tax benefit of these items was not recognized in the accounts as it has been fully provided for. Unrecognized Tax Benefits The Company does not have any unrecognized tax benefits. Tax Years and Examination The Company files tax returns in each jurisdiction in which it is registered to do business. For each jurisdiction a statute of limitations period exists. After a statute of limitations period expires, the respective tax authorities may no longer assess additional income tax for the expired period. Similarly, the Company is no longer eligible to file claims for refund for any tax that it may have overpaid. The following table summarizes the Company's major tax jurisdictions and the tax years that remain subject to examination by these jurisdictions as of December 31, 2019: Tax Jurisdictions Tax Years Federal - Canada 2015 and onward Provincial - Quebec 2015 and onward Federal - USA 2015 onward |
Revenues
Revenues | 12 Months Ended |
Dec. 31, 2019 | |
Revenue from Contract with Customer [Abstract] | |
Revenues | 17. Revenues The following table presents our revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues: December 31, 2019 December 31, 2018 Research and development agreements $ 742 $ 1,824 The following table presents our revenues disaggregated by timing of recognition: December 31, 2019 December 31, 2018 Product and services transferred at point in time $ 372 $ — Products and services transferred over time 370 1,824 $ 742 $ 1,824 The following table presents our revenues disaggregated by geography, based on the billing addresses of our customers: December 31, 2019 December 31, 2018 Europe $ 534 1,715 Canada 208 109 $ 742 $ 1,824 As at December 31, 2019, the aggregate amount of the transaction price allocated to the remaining performance obligation is $1,084 representing research and development agreements, the majority of which is expected to be recognized in the next twelve months. The Company is also eligible to receive up to $4,169 in research and development milestone payments, approximately 60% of which is expected to be recognized in the next three years, with the remaining 40% expected in the two years following; up to $28,376 in commercial sales milestone payments which are wholly dependent on the marketing efforts of our development partners. In addition, the Company is entitled to receive royalties on potential sales. The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about the remaining performance obligations that have original expected durations of one year or less. |
Statement of Cash Flows Informa
Statement of Cash Flows Information | 12 Months Ended |
Dec. 31, 2019 | |
Supplemental Cash Flow Information [Abstract] | |
Statement of Cash Flows Information [Text Block] | 18. Statement of Cash Flows Information In US$ thousands 2019 2018 Additional Cash Flow Information: Interest paid $ 465 $ 476 |
Leases
Leases | 12 Months Ended |
Dec. 31, 2019 | |
Leases [Abstract] | |
Leases [Text Block] | 19. Leases Substantially all our operating lease right-of-use assets and operating lease liability represents leases for office space and property to conduct our business. The operating lease expense for the year ended December 31, 2019 included in general and administrative expenses is $152 thousand. The cash outflows from operating leases for the year ended December 31, 2019 was $144 thousand. The weighted average remaining lease term and the weighted average discount rate for operating leases at December 31, 2019 were 6.2 years and 10%, respectively. The following table reconciles the undiscounted cash flows for the operating leases as et December 31, 2019 to the operating lease liabilities recorded on the balance sheet: Operating Leases 2020 $ 150 2021 152 2022 156 2023 158 2024 161 Thereafter 188 Total undiscounted lease payments 965 Less: Interest 273 Present value of lease liabilities $ 692 Current portion of operating lease liability $ 137 Operating lease liability $ 555 |
Related Party Transactions
Related Party Transactions | 12 Months Ended |
Dec. 31, 2019 | |
Related Party Transactions [Abstract] | |
Related Party Transactions [Text Block] | 20. Related party transactions Included in management salaries are $67 thousand (2018 - $75 thousand) for options and PRSUs granted to the Chief Executive Officer, $50 thousand (2018 - $46 thousand) for options and PRSUs granted to the President and Chief Financial Officer, $29 thousand (2018 - $24) for options granted to the Vice-President, Research and Development, $29 thousand (2018 - $54) for options granted to the Vice-President, Business and Corporate Development, and $36 thousand (2018 - $12) for options granted to the Vice-President, Operations under the 2016 Stock Option Plans and$Nil (2018 - $11 thousand) for options granted to non-employee directors. Included in general and administrative expenses are director fees of $231 thousand (2018: $250 thousand). The above related party transactions have been measured at the exchange amount which is the amount of the consideration established and agreed upon by the related parties. |
Basic and Diluted Loss Per Comm
Basic and Diluted Loss Per Common Share | 12 Months Ended |
Dec. 31, 2019 | |
Earnings Per Share [Abstract] | |
Basic and Diluted Loss Per Common Share [Text Block] | 21. Basic and Diluted Loss Per Common Share Basic and diluted loss per common share is calculated based on the weighted average number of shares outstanding during the year. Common equivalent shares from stock options, warrants and convertible debentures are also included in the diluted per share calculations unless the effect of the inclusion would be antidilutive. |
Subsequent Event
Subsequent Event | 12 Months Ended |
Dec. 31, 2019 | |
Subsequent Events [Abstract] | |
Subsequent Event [Text Block] | 22. Subsequent events On February 11, 2020, the Company announced that it has closed its offering (the "Offering") of 16,317,000 units (the "Units") at a price of CAD$0.50 per Unit (the "Offering Price") for gross proceeds of CAD$8,158,500. Each Unit consists of one share of common stock (the "Offered Shares") and one warrant (a "Warrant") entitling the holder to purchase one share of common stock of the Company at an exercise price of CAD$0.75 per share (a "Warrant Share"). The Warrants are exercisable immediately and will expire on the third anniversary of the date of their issuance. The Units were distributed under a short form prospectus dated January 27, 2020 filed by the Company in connection with the Offering and have been registered with the United States Securities and Exchange Commission pursuant to a Form S-1 Registration Statement that was declared effective on January 31, 2020 (the "Registration Statement"). The Offering was conducted, on a best efforts basis, by Echelon Wealth Partners Inc. (the "Agent"). In consideration for the services rendered by the Agent, the Company has paid the Agent an agency fee equal to 7% of the gross proceeds of the Offering and has issued the Agent a number of warrants (the "Agent Warrants") equal to 7% of the number of Units issued under the Offering, each Agent Warrant entitling the holder to purchase one share of common stock of the Company at an exercise price of CAD$0.75 per share until the third anniversary of the date of their issuance. After the payment of the Agent's commissions and the reimbursement of certain of the Agent's Offering expenses and the payment of other Offering expenses, the Company expects the net proceeds from the Offering to be approximately CAD$7.4 million. The TSX Venture Exchange (the "TSXV") has approved the listing of the Warrants and the common stock that will be issued by the Company in the Offering, including the shares of common stock issuable upon the exercise of the Warrants and the Agent Warrants. The Warrants are listed on the TSXV under the symbol "IGX.WT" and commenced trading effective at the opening of the market on Thursday, February 13, 2020. On March 11, 2020, the World Health Organization declared the outbreak of a novel coronavirus (“COVID-19”) as a global pandemic, which continues to spread throughout Canada and around the world. On March 23, 2020, the government of Quebec ordered the closure of all non-essential businesses effective March 25, 2020, through April 13, 2020. Because of the nature of its operations, the Company is only partially affected by this order. As of March 26, 2020, the Company is aware of the impact on its business as a result of COVID-19 but uncertain as to the extent of this impact on its consolidated financial statements. This partial disruption, even temporary, may impact our operations and overall business by delaying the progress of our research and development programs and production activities. There is uncertainty as to the duration and hence the potential impact. As a result, we are unable to estimate the potential impact on our business as of the date of this filing. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2019 | |
Accounting Policies [Abstract] | |
Revenue [Policy Text Block] | Revenue Recognition The Company may enter into licensing and collaboration agreements for product development, licensing, supply and manufacturing for its product pipeline. The terms of the agreements may include non-refundable signing and licensing fees, milestone payments and royalties on any product sales derived from collaborations. These contracts are analyzed to identify all performance obligations forming part of these contracts. The transaction price of the contract is then determined. The transaction price is allocated between all performance obligations on a residual standalone selling price basis. The stand-alone selling price is estimated based on the comparable market prices, expected cost plus margin and the Company's historical experience. Revenue is measured based on a consideration specified in a contract with a customer, and excludes any sales incentives and amounts collected on behalf of third parties. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a product or service to a customer. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. The following is a description of principal activities - separated by nature - from which the Company generates its revenue. Research and Development Revenue Revenues with corporate collaborators are recognized as the performance obligations are satisfied over time, and the related expenditures are incurred pursuant to the terms of the agreement. Licensing and Collaboration Arrangements Licenses are considered to be right-to-use licenses. As such, the Company recognizes the licenses revenues at a point in time, upon granting the licenses. Milestone payments are considered variable consideration. As such, the Company estimates variable consideration at the most likely amount to which we expect to be entitled. The estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, research and other revenues in the period during which the adjustment is recognized. The process of successfully achieving the criteria for the milestone payments is highly uncertain. Consequently, there is significant risk that the Company may not earn all of the milestone payments for each of its contracts. Royalties are typically calculated as a percentage of net sales realized by the Company's licensees of its products (including their sub-licensees), as specifically defined in each agreement. The licensees' sales generally consist of revenues from product sales of the Company's product pipeline and net sales are determined by deducting the following: estimates for chargebacks, rebates, sales incentives and allowances, returns and losses and other customary deductions in each region where the Company has licensees. Revenues arising from royalties are considered variable consideration. As such, the Company estimates variable consideration at the most likely amount to which we expect to be entitled. The estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. |
Use of Estimates [Policy Text Block] | Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The financial statements include estimates based on currently available information and management's judgment as to the outcome of future conditions and circumstances. Significant estimates in these financial statements include the useful lives and impairment of long-lived assets, stock-based compensation costs, and the investment tax credits receivable. Changes in the status of certain facts or circumstances could result in material changes to the estimates used in the preparation of the financial statements and actual results could differ from the estimates and assumptions. |
Accounts Receivable [Policy Text Block] | Accounts Receivable The Company accounts for trade receivables at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a quarterly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer's financial condition, credit history and current economic conditions. The Company writes off trade receivables when they are deemed uncollectible and records recoveries of trade receivables previously written off when they receive them. Management has determined that no allowance for doubtful accounts is necessary in order to adequately cover exposure to loss in its December 31, 2019 accounts receivable (2018: $). A bad debt expense in the amount of $ (2018: $) is recorded in the year ended December 31, 2019. |
Investment Tax Credits [Policy Text Block] | Investment Tax Credits Investment tax credits relating to qualifying expenditures are recognized in the accounts at the time at which the related expenditures are incurred and there is reasonable assurance of their realization. Management has made estimates and assumptions in determining the expenditures eligible for investment tax credits claimed. Investment tax credits received in the year ended December 31, 2019 totaled $416 thousand (2018: $289). |
Inventory, Policy [Policy Text Block] | Inventory The Company values inventory at the lower of cost and net realizable value where net realizable value represents the expected sale price upon disposition less make-ready costs and the costs of disposal and transportation and determines the cost of raw material inventory using the average-cost method. The Company analyzes its inventory levels quarterly and adjusts inventory to its net realizable value, if required, for obsolete, or has a cost basis in excess of its expected net realizable value. |
Leasehold Improvements and Equipment [Policy Text Block] | Leasehold Improvements and Equipment Leasehold improvements and equipment are recorded at cost. Provisions for depreciation are based on their estimated useful lives using the methods as follows: On the declining balance method - Laboratory and office equipment 20% Computer equipment 30% On the straight-line method - Leasehold improvements over the lease term Manufacturing equipment 5 - 10 years Upon retirement or disposal, the cost of the asset disposed of and the related accumulated depreciation are removed from the accounts and any gain or loss is reflected in income. Expenditures for repair and maintenance are expensed as incurred. |
Leases [Policy Text Block] | Leases Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: the lease transfers ownership of the asset by the end of the lease term, the lease contains an option to purchase the asset that is reasonably certain to be exercised, the lease term is for a major part of the remaining useful life of the asset or the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it does not meet any one of these criteria. Substantially all of the Company's operating leases are comprised of office space and property leases and the Company does not hold any finance leases. For all leases at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial costs incurred, consisting mainly of brokerage commissions, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's secured incremental borrowing rate for the same term as the underlying lease. Lease payments included in the measurement of the lease liability comprise the following: the fixed noncancelable lease payments, payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, and payments for early termination options unless it is reasonably certain the lease will not be terminated early. Lease modifications result in remeasurement of the lease liability. Lease expense for operating leases consists of the lease payments plus any initial direct costs, primarily brokerage commissions, and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability. The Company has elected not to recognize right-of-use assets and lease liabilities for short-tern leases that have a term of 12 months or less. The effect of short-term leases on our right-of-use asset and lease liability was not material. |
Security Deposits [Policy Text Block] | Security Deposits Security deposits represent a refundable deposit paid to the landlord in accordance with the lease agreement and deposits held as guarantees by the Company's lenders in accordance with the lending facilities. The deposits will be repaid to the Company at the end of the lease. |
Impairment of Long-lived Assets [Policy Text Block] | Impairment of Long-lived Assets Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the estimated undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value there of. |
Foreign Currency Translation [Policy Text Block] | Foreign Currency Translation The Company's reporting currency is the U.S. dollar. The Canadian dollar is the functional currency of the Company's Canadian operations, which is translated to the United States dollar using the current rate method. Under this method, accounts are translated as follows: Gains and losses arising from foreign currency translation are included in other comprehensive income. |
Income Taxes [Policy Text Block] | Income Taxes The Company accounts for income taxes in accordance with FASB ASC 740 "Income Taxes". Deferred taxes are provided on the liability method whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. |
Unrecognized Tax Benefits [Policy Text Block] | Unrecognized Tax Benefits The Company accounts for unrecognized tax benefits in accordance with FASB ASC 740 "Income Taxes". ASC 740 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. ASC 740 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon ultimate settlement with a taxing authority, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. Additionally, ASC 740 requires the Company to accrue interest and related penalties, if applicable, on all tax positions for which reserves have been established consistent with jurisdictional tax laws. The Company elected to classify interest and penalties related to the unrecognized tax benefits in the income tax provision. |
Share-based Payment Arrangement [Policy Text Block] | Share-Based Payments The Company accounts for share-based payments to employees in accordance with the provisions of FASB ASC 718 "Compensation-Stock Compensation" and accordingly recognizes in its financial statements share-based payments at their fair value. In addition, the Company will recognize in the financial statements an expense based on the grant date fair value of stock options granted to employees. The expense will be recognized on a straight-line basis over the vesting period and the offsetting credit will be recorded in additional paid-in capital. Upon exercise of options, the consideration paid together with the amount previously recorded as additional paid-in capital will be recognized as capital stock. The Company uses the Black-Scholes option pricing model to determine the fair value of the options. The Company measures compensation expense for its non-employee stock-based compensation under ASC 718, "Compensation-Stock Compensation" and accordingly recognizes in its financial statements share-based payments at their fair value. In addition, the Company will recognize in the financial statements as expense over the service period, as if the Company had paid cash for the services. |
Loss Per Share [Policy Text Block] | Loss Per Share Basic loss per share is calculated based on the weighted average number of shares outstanding during the year. Any antidilutive instruments are excluded from the calculation of diluted loss per share. |
Fair Value Measurements [Policy Text Block] | Fair Value Measurements ASC 820 applies to all assets and liabilities that are being measured and reported on a fair value basis. ASC 820 requires disclosure that establishes a framework for measuring fair value in US GAAP, and expands disclosure about fair value measurements. This statement enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The statement requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories: Level 1: Level 2: Level 3: In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are subject to ASC 820. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. Short-term investments are classified Level 1. |
Fair Value of Financial Instruments [Policy Text Block] | Fair Value of Financial Instruments The fair value represents management's best estimates based on a range of methodologies and assumptions. The carrying value of receivables and payables arising in the ordinary course of business and the investment tax credits receivable approximate fair value because of the relatively short period of time between their origination and expected realization. |
Recent Accounting Pronouncements [Policy Text Block] | Recent Accounting Pronouncements ASU 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes The FASB issued ASU 2019-12 which removes specific exceptions to the general principles in Topic 740 in Generally Accepted Accounting Principles (GAAP). It eliminates the need for an organization to analyze whether the following apply in a given period: -Exception to the incremental approach for intraperiod tax allocation; -Exceptions to accounting for basis differences when there are ownership changes in foreign investments; and -Exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses. The ASU also improves financial statement preparers' application of income tax-related guidance and simplifies GAAP for: -Franchise taxes that are partially based on income; -Transactions with a government that result in a step up in the tax basis of goodwill; -Separate financial statements of legal entities that are not subject to tax; and -Enacted changes in tax laws in interim periods. These amendments are effective for fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. ASU 2019-11 Codification Improvements to Topic 326, Financial Instruments - Credit Losses The FASB issued ASU 2019-11 which clarifies guidance around how to report expected recoveries. "Expected recoveries" describes a situation in which an organization recognizes a full or partial writeoff of the amortized cost basis of a financial asset, but then later determines that the amount written off, or a portion of that amount, will in fact be recovered. This ASU permits organizations to record expected recoveries on PCD assets. These amendments are effective for fiscal years beginning after December 15, 2019. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. ASU 2019-08 Compensation - Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Codification Improvements - Share-Based Consideration Payable to a Customer The FASB issued ASU 2019-08 which requires companies to measure and classify (on the balance sheet) share-based payments to customers by applying the guidance in Topic 718, Compensation-Stock Compensation. As a result, the amount recorded as a reduction in revenue would be measured based on the grant-date fair value of the share-based payment. These amendments are effective for fiscal years beginning after December 15, 2019. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. ASU 2019-05 Credit Losses (Topic 326): Targeted Transition Relief The FASB issued ASU 2019-05 which provides entities that have certain instruments within the scope of Subtopic 326-20, Financial Instruments - Credit Losses - Measured at Amortized Cost, with an option to irrevocably elect the fair value option in Subtopic 825-10, Financial Instruments - Overall, applied on an instrument-by-instrument basis for eligible instruments, upon adoption of Topic 326. The fair value option election does not apply to held-to-maturity debt securities. An entity that elects the fair value option should subsequently apply the guidance in Subtopics 820-10, Fair Value Measurement - Overall, and 825-10. These amendments are effective for fiscal years beginning after December 15, 2019. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. ASU 2018-19 Codification Improvements to Topic 326, Financial Instruments-Credit Losses The FASB issued ASU 2018-19 which mitigates transition complexity by requiring entities other than public business entities, including not-for-profit organizations and certain employee benefit plans, to implement the credit losses standard issued in 2016, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. This aligns the implementation date for their annual financial statements with the implementation date for their interim financial statements. The guidance also clarifies that receivables arising from operating leases are not within the scope of the credit losses standard, but rather, should be accounted for in accordance with the leases standard. These amendments are effective for fiscal years beginning after December 15, 2019. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. ASU 2018-18 Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606 The FASB issued ASU 2018-18 which provides guidance on how to assess whether certain transactions between collaborative arrangement participants should be accounted for within the revenue recognition standard. The ASU also provides more comparability in the presentation of revenue for certain transactions between collaborative arrangement participants. It accomplishes this by allowing organizations to only present units of account in collaborative arrangements that are within the scope of the revenue recognition standard together with revenue accounted for under the revenue recognition standard. The parts of the collaborative arrangement that are not in the scope of the revenue recognition standard should be presented separately from revenue accounted for under the revenue recognition standard. These amendments are effective for fiscal years beginning after December 15, 2019. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. ASU 2018-13 - Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement The FASB issued ASU 2018-13 which modifies the disclosure requirements in Topic 820 as follows: Removals -The amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; -The policy for timing of transfers between levels; -The valuation processes for Level 3 fair value measurements; and -For nonpublic entities, the changes in unrealized gains and losses for the period included in earnings for recurring Level 3 fair value measurements held at the end of the reporting period. Modifications -In lieu of a rollforward for Level 3 fair value measurements, a nonpublic entity is required to disclose transfers into and out of Level 3 of the fair value hierarchy and purchases and issues of Level 3 assets and liabilities; -For investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee's assets and the date when restrictions from redemption might lapse only if the investee has communicated the timing to the entity or announced the timing publicly; and -The amendments clarify that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date Additions -The changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period; and - The range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. For certain unobservable inputs, an entity may disclose other quantitative information (such as the median or arithmetic average) in lieu of the weighted average if the entity determines that other quantitative information would be a more reasonable and rational method to reflect the distribution of unobservable inputs used to develop Level 3 fair value measurements. These amendments are effective for fiscal years beginning after December 15, 2019. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. |
Adoption of New Accounting St_2
Adoption of New Accounting Standards (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
New Accounting Pronouncements and Changes in Accounting Principles [Abstract] | |
Schedule of impact of the adoption of ASC 842 on the balance sheet [Table Text Block] | As reported December 31, 2018 Adoption of ASC 842 Increase (Decrease) Balance January 1, 2019 Operating lease right-of-use assets $ — $ 726 $ 726 Total assets 20,018 726 20,744 Total current liabilities 2,722 127 2,849 Deferred lease obligations 49 (49 ) — Operating lease liability — 599 599 Total liabilities 10,031 677 10,708 Total shareholders' equity 9,987 49 10,036 Total liabilities and shareholders' equity 20,018 726 20,744 |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Notes to Financial Statements [Abstract] | |
Schedule of estimated useful lives of leasehold improvements and equipment [Table Text Block] | On the declining balance method - Laboratory and office equipment 20% Computer equipment 30% On the straight-line method - Leasehold improvements over the lease term Manufacturing equipment 5 - 10 years |
Leasehold Improvements and Eq_2
Leasehold Improvements and Equipment (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Notes to Financial Statements [Abstract] | |
Schedule of leasehold improvements and equipment [Table Text Block] | 2019 2018 Accumulated Net Carrying Net Carrying Cost Depreciation Amount Amount Manufacturing equipment $ 4,657 $ 879 $ 3,778 $ 3,512 Laboratory and office equipment 1,368 870 498 562 Computer equipment 125 85 40 39 Leasehold improvements 3,325 1,276 2,049 2,135 $ 9,475 $ 3,110 $ 6,365 $ 6,248 |
Long-term debt (Tables)
Long-term debt (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Other Liabilities Disclosure [Abstract] | |
Schedule of term loan [Table Text Block] | December 31, 2019 December 31, 2018 $ $ Term loan facility 1,005 1,502 Secured loan 192 330 Total debt 1,197 1,832 Less: current portion 727 692 Total long-term debt 470 1,140 |
Schedule of term loan principal repayments [Table Text Block] | 2020 727 (CAD 945) 2021 470 (CAD 610) |
Convertible Debentures (Tables)
Convertible Debentures (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Convertible Debt [Abstract] | |
Schedule of convertible debt [Table Text Block] | December 31, December 31, 2019 2018 Face value of the convertible debentures $ 5,835 $ 5,556 Transaction costs (952 ) (907 ) Accretion 759 398 Convertible debentures $ 5,642 $ 5,047 |
Convertible Note (Tables)
Convertible Note (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Convertible Notes [Abstract] | |
Schedule of Capital Units [Table Text Block] | Gross proceeds Transaction costs Net proceeds Common stock $ 1,627 $ 167 $ 1,460 Convertible notes 1,086 111 975 Warrants 487 50 437 $ 3,200 $ 328 $ 2,872 |
Schedule of Components of the Convertible Notes [Table Text Block] | December 31, December 31, 2019 2018 Attributed value of net proceeds to convertible notes $ 975 975 Accretion 280 98 Convertible notes $ 1,255 1,073 |
Capital Stock (Tables)
Capital Stock (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Stockholders' Equity Note [Abstract] | |
Schedule of Stock by Class [Table Text Block] | 2019 2018 Authorized - 200,000,000 common shares of $0.00001 par value 20,000,000 preferred shares of $0.00001 par value Issued - 93,942,652 (December 31, 2018: 93,477,473) common shares $ 1 $ 1 |
Schedule Of Proceeds Of Equity Components Based On Fair Value [Table Text Block] | Gross proceeds Transaction costs Net proceeds Common stock $ 10,926 $ 1,739 $ 9,187 Warrants 1,708 272 1,436 $ 12,634 $ 2,011 $ 10,623 |
Additional Paid-In Capital (Tab
Additional Paid-In Capital (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Schedule of Additional Paid In Capital [Line Items] | |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | 2019 2018 Exercise price 0.69 0.74 Expected volatility 64% 5.9% Expected life 5.63 years 5.63 years Risk‑free interest rate 2.18% 2.73% Dividend yield Nil Nil |
Share-based Payment Arrangement, Option, Activity [Table Text Block] | Weighted average Number of options exercise price Outstanding – January 1, 2018 2,939,818 0.65 Granted 1,250,000 0.74 Forfeited (175,000 ) (0.69 ) Expired (100,000 ) (0.52 ) Exercised (60,000 ) (0.56 ) Outstanding – December 31, 2018 3,854,818 0.68 Granted 100,000 0.69 Forfeited (37,500 ) (0.66 ) Expired (402,500 ) (0.67 ) Exercised (50,000 ) (0.41 ) Outstanding – December 31, 2019 3,464,818 0.68 |
Schedule of Stock Option Activity to Consultants [Table Text Block] | Weighted average Number of options exercise price $ Outstanding – January 1, 2018 50,000 0.73 Granted 500,000 0.72 Outstanding – December 31, 550,000 0.72 |
Schedule of Share-based Compensation, Stock Options, and Warrants or Rights Activity [Table Text Block] | Outstanding options Exercisable options Weighted Weighted Weighted average average Aggregate average Aggregate Exercise Number of remaining exercise intrinsic Number of exercise intrinsic prices options contractual life price value options price value $ (years) $ $ $ $ 0.41 275,000 0.07 0.03 275,000 0.03 0.58 675,000 0.09 0.10 675,000 0.12 0.62 150,000 0.01 0.02 150,000 0.03 0.66 200,000 0.41 0.03 150,000 0.03 0.69 100,000 0.23 0.02 25,000 0.01 0.70 475,000 0.35 0.08 237,500 0.05 0.73 525,000 0.82 0.10 525,000 0.11 0.76 905,000 1.87 0.17 705,000 0.16 0.77 359,818 0.69 0.07 359,818 0.08 0.78 100,000 0.04 0.02 50,000 0.01 0.89 250,000 0.44 0.06 250,000 0.07 4,014,818 5.02 0.70 16,500 3,402,318 0.70 16,500 |
Schedule of Stockholders' Equity Note, Warrants or Rights, Activity [Table Text Block] | Number of Weighted average warrants exercise price (All Exercisable) $ Outstanding - January 1, 2018 4,070,902 0.5646 Granted 12,954,397 0.9464 Exercised (4,044,606 ) (0.5675 ) Expired (76,296 ) (0.5646 ) Outstanding - 12,904,397 0.9470 |
Income Tax (Tables)
Income Tax (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Income Tax Disclosure [Abstract] | |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | 2019 2018 Statutory income taxes $ (2,398 ) $ (2,421 ) Net operating losses for which no tax benefits have been recorded 1,189 1,185 Deficiency of depreciation over capital cost allowance (178 ) (236 ) Non-deductible expenses 667 422 Undeducted research and development expenses 820 1,167 Investment tax credit (100 ) (117 ) $ — $ — |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | 2019 2018 Leasehold improvements and equipment $ 440 $ 418 Net operating losses carryforward 6,396 4,170 Undeducted research and development expenses 2,903 2,774 Non-refundable tax credits carryforward 2,082 1,982 11,821 9,344 Valuation allowance (11,821 ) (9,344 ) $ — $ — |
Schedule of Tax years and Jurisdictions [Table Text Block] | Tax Jurisdictions Tax Years Federal - Canada 2015 and onward Provincial - Quebec 2015 and onward Federal - USA 2015 onward |
Revenues (Tables)
Revenues (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Revenue from Contract with Customer [Abstract] | |
Disaggregation of Revenue [Table Text Block] | December 31, 2019 December 31, 2018 Research and development agreements $ 742 $ 1,824 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block] | December 31, 2019 December 31, 2018 Product and services transferred at point in time $ 372 $ — Products and services transferred over time 370 1,824 $ 742 $ 1,824 |
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] | December 31, 2019 December 31, 2018 Europe $ 534 1,715 Canada 208 109 $ 742 $ 1,824 |
Statement of Cash Flows Infor_2
Statement of Cash Flows Information (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Supplemental Cash Flow Information [Abstract] | |
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] | In US$ thousands 2019 2018 Additional Cash Flow Information: Interest paid $ 465 $ 476 |
Leases (Tables)
Leases (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Leases [Abstract] | |
Schedule of reconciles undiscounted cash flows for operating leases [Table Text Block] | Operating Leases 2020 $ 150 2021 152 2022 156 2023 158 2024 161 Thereafter 188 Total undiscounted lease payments 965 Less: Interest 273 Present value of lease liabilities $ 692 |
Schedule of operating lease liabilities [Table Text Block] | Current portion of operating lease liability $ 137 Operating lease liability $ 555 |
Going Concern (Narrative) (Deta
Going Concern (Narrative) (Details) | Feb. 11, 2020CAD ($)$ / sharesshares | Oct. 26, 2018USD ($) | Oct. 22, 2018USD ($)$ / sharesshares | Dec. 31, 2018USD ($) | Dec. 31, 2019USD ($)$ / shares |
Going Concern [Line Items] | |||||
Cash and short-term investments | $ 1,912,000 | ||||
Proceeds from offering | $ 11,405,000 | ||||
Public Offering [Member] | |||||
Going Concern [Line Items] | |||||
Number of closing units | shares | 17,144,314 | ||||
Share Price | $ / shares | $ 0.70 | $ 1 | |||
Proceeds from offering | $ 632,527 | $ 12,000,000 | |||
Public Offering [Member] | Subsequent Event [Member] | |||||
Going Concern [Line Items] | |||||
Number of closing units | shares | 16,317,000 | ||||
Share Price | $ / shares | $ 0.50 | ||||
Proceeds from offering | $ 8,158,500 |
Adoption of New Accounting St_3
Adoption of New Accounting Standards (Narrative) (Details) - USD ($) $ in Thousands | Dec. 31, 2019 | Dec. 31, 2018 |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Operating lease right-of-use assets related to operating lease liability | $ 683 | |
Accounting Standards Update 842 [Member] | ||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Operating lease right-of-use assets related to operating lease liability | $ 726 | |
Accounting Standards Update 842 [Member] | Restatement Adjustment [Member] | ||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Operating lease right-of-use assets related to operating lease liability | $ 726 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies (Narrative) (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
Accounting Policies [Abstract] | ||
Allowance for Doubtful Accounts Receivable | ||
Bad debt expense | ||
Investment Tax Credit | $ 416 | $ 289 |
Short-term investments (Narrati
Short-term investments (Narrative) (Details) $ in Thousands, $ in Thousands | Dec. 31, 2019CAD ($) | Dec. 31, 2019USD ($) | Dec. 31, 2018CAD ($) | Dec. 31, 2018USD ($) |
Cash and Cash Equivalents [Line Items] | ||||
Short-term investments | $ 580 | $ 4,180 | ||
Mutual Fund [Member] | ||||
Cash and Cash Equivalents [Line Items] | ||||
Short-term investments | $ 754 | $ 580 | $ 5,703,000 | $ 4,180,000 |
Inventory (Narrative) (Details)
Inventory (Narrative) (Details) - USD ($) $ in Thousands | Dec. 31, 2019 | Dec. 31, 2018 |
Inventory Disclosure [Abstract] | ||
Raw materials inventory | $ 382 | $ 375 |
Leasehold Improvements and Eq_3
Leasehold Improvements and Equipment (Narrative) (Details) - USD ($) $ in Thousands | Dec. 31, 2019 | Dec. 31, 2018 |
Property, Plant and Equipment, Net | $ 6,365 | $ 6,248 |
Asset not yet in service [Member] | ||
Property, Plant and Equipment, Net | $ 1,788 | $ 1,703 |
Bank indebtedness (Narrative) (
Bank indebtedness (Narrative) (Details) - 12 months ended Dec. 31, 2019 | CAD ($) | USD ($) |
Line of Credit Facility [Line Items] | ||
Line of Credit Facility, Interest Rate Description | Bank's prime lending rate plus 2% | |
Line of Credit Facility, Collateral | The credit facility and term loan (see note 10) are secured by a first ranking movable hypothec on all present and future movable property of the Company for an amount of CAD$4,250,000 ($3,272,000) plus 20%, and a 50% guarantee by Export Development Canada, a Canadian Crown corporation export credit agency. | |
Line Of Credit Facility, Collateral Amount | $ 4,250,000 | $ 3,272,000 |
Line of Credit [Member] | ||
Line of Credit Facility [Line Items] | ||
Long-term Line of Credit | 250,000 | 192,000 |
Corporate Credit Cards [Member] | ||
Line of Credit Facility [Line Items] | ||
Long-term Line of Credit | 75,000 | 58,000 |
Foreign Exchange Contract [Member] | ||
Line of Credit Facility [Line Items] | ||
Long-term Line of Credit | $ 425,000 | $ 327,000 |
Long-term debt (Narrative) (Det
Long-term debt (Narrative) (Details) | 12 Months Ended | ||||
Dec. 31, 2019CAD ($) | Dec. 31, 2019USD ($) | Dec. 31, 2019USD ($) | Jul. 12, 2017CAD ($) | Jul. 12, 2017USD ($) | |
Debt Instrument [Line Items] | |||||
Aggregate principal amount | $ 6,838,000 | $ 5,265,000 | |||
Term loan facility [Member] | |||||
Debt Instrument [Line Items] | |||||
Aggregate principal amount | $ 4,000,000 | $ 3,080,000 | |||
Debt Instrument, Interest Rate Terms | Bank’s prime lending rate plus 2.50% | Bank’s prime lending rate plus 2.50% | |||
Debt Instrument, Periodic Payment | $ 62,000 | $ 48,000 | |||
Secured Loan [Member] | |||||
Debt Instrument [Line Items] | |||||
Aggregate principal amount | $ 1,000,000 | $ 770,000 | |||
Debt Instrument, Interest Rate Terms | bearing interest at prime plus 7.3% | bearing interest at prime plus 7.3% | |||
Debt Instrument, Periodic Payment | $ 17,000 | $ 13,000 |
Convertible Debentures (Narrati
Convertible Debentures (Narrative) (Details) | Aug. 08, 2017CAD ($) | Aug. 08, 2017USD ($) | Jul. 12, 2017CAD ($)$ / sharesshares | Jul. 12, 2017USD ($) | Dec. 28, 2018CAD ($) | Dec. 28, 2018USD ($) | Aug. 08, 2017CAD ($) | Dec. 31, 2019CAD ($)shares | Dec. 31, 2019USD ($)shares | Dec. 31, 2018CAD ($)shares | Dec. 31, 2018USD ($)shares | May 08, 2018$ / shares | Jul. 12, 2017USD ($)$ / sharesshares |
Convertible Debentures [Line Items] | |||||||||||||
Net proceeds from issuance of convertible debentures | $ 762,000 | $ 587,000 | $ 6,838,000 | $ 5,265,000 | $ 7,600,000 | ||||||||
Proceeds from Convertible Debt, amount per instrument | 1,000 | $ 770 | |||||||||||
Aggregate principal amount | $ 6,838,000 | $ 5,265,000 | |||||||||||
Debt Instrument, Interest Rate | 8.00% | 8.00% | |||||||||||
Debt Instrument, Convertible, Conversion Price | (per share) | $ 1.35 | $ 0.80 | $ 1.04 | ||||||||||
Debt Instrument, Convertible, Number of shares per instrument | 740 | 740 | |||||||||||
Transaction costs | $ 1,237,000 | $ 952,000 | $ 907,000 | ||||||||||
Accretion Expense | 443,000 | 334,000 | $ 383,000 | 296,000 | |||||||||
Convertible debentures were converted into common stock, Value | 23,000 | 17,000 | |||||||||||
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt | $ | 16,000 | ||||||||||||
Interest on Convertible Debt, Net of Tax | 606,000 | 457,000 | 607,000 | 468,000 | |||||||||
Interest paid by issuance of common shares | $ 303,000 | $ 228,000 | $ 304,000 | $ 231,000 | |||||||||
Interest paid by issuance of common shares (Shares) | 415,179 | 415,179 | 307,069 | 307,069 | |||||||||
Interest paid on convertible debentures | $ 303,000 | $ 237,000 | $ 303,000 | $ 229,000 | |||||||||
Common Stock [Member] | |||||||||||||
Convertible Debentures [Line Items] | |||||||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities | 17,036 | 17,036 |
Convertible Notes (Narrative) (
Convertible Notes (Narrative) (Details) | May 08, 2018USD ($)$ / sharesshares | Dec. 31, 2019USD ($)shares | Dec. 31, 2018CAD ($)shares | Dec. 31, 2018USD ($)shares | Nov. 13, 2018$ / shares | Jul. 12, 2017$ / shares | Jul. 12, 2017$ / shares |
Debt Instrument [Line Items] | |||||||
Stock Issued During Period, Shares, Conversion of Units | shares | 320 | ||||||
Subscription Price of Units | $ 10,000 | ||||||
Stock Issued During Period, Value, Conversion of Units | $ 3,200,000 | ||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | $ 23,000 | $ 17,000 | |||||
Warrants Issued During Period, Warrants | shares | 7,690 | ||||||
Interest Rate on Convertible Note | 6.00% | ||||||
Debt Instrument, Convertible, Conversion Price | (per share) | $ 0.80 | $ 1.35 | $ 1.04 | ||||
Sale of Stock, Price Per Share | $ / shares | $ 0.80 | $ 0.70 | |||||
Commission Paid to Agents | $ 157,800 | ||||||
Stock Issued During Period, Shares, Issued for Services | shares | 243,275 | ||||||
Equity Issuance, Per Share Amount | $ / shares | $ 0.80 | ||||||
Warrants Issued During Period, Value | $ 50,000 | ||||||
Accretion Expense | $ 514,000 | 396,000 | |||||
Financing Interest Expense | 96,000 | $ 63,000 | |||||
ASU 2014-13, Consolidation (Topic 810) Measuring the Financial Assets and the Financial Liabilities of a Consolidated Collateralized Financing Entity [Policy Text Block] | 1,897 | ||||||
Net Proceeds of Units | $ 2,872,000 | ||||||
Convertible debt securities [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities | shares | 7,940 | ||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | $ 5,000 | ||||||
Interest Rate on Convertible Note | 6.00% | ||||||
Common stock [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities | shares | 17,036 | 17,036 | |||||
Net Proceeds of Units | $ 1,460,000 | ||||||
Warrants [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Net Proceeds of Units | 437,000 | ||||||
Convertible notes [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Transactions Costs of Convertible Notes | 111,000 | ||||||
Accretion Expense | 182,000 | $ 98,000 | |||||
Net Proceeds of Units | $ 975,000 |
Commitments (Narrative) (Detail
Commitments (Narrative) (Details) € in Thousands | Dec. 31, 2019EUR (€) |
Commitments and Contingencies Disclosure [Abstract] | |
Purchase Obligation | € 1,911 |
Payments made in respect to purchase obligation | € 1,425 |
Capital Stock (Narrative) (Deta
Capital Stock (Narrative) (Details) | Nov. 13, 2018USD ($)$ / sharesshares | May 08, 2018USD ($)$ / sharesshares | Oct. 26, 2018USD ($)shares | Oct. 22, 2018USD ($)$ / sharesshares | Dec. 31, 2019USD ($)$ / sharesshares | Dec. 31, 2018CAD ($)shares | Dec. 31, 2018USD ($)shares | Jul. 12, 2017$ / shares | Jul. 12, 2017$ / shares |
Class of Stock [Line Items] | |||||||||
Stock Issued During Period, Shares, Conversion of Units | shares | 320 | ||||||||
Subscription Price of Units | $ 10,000 | ||||||||
Stock Issued During Period, Value, Conversion of Units | $ 3,200,000 | ||||||||
Convertible debentures were converted into common stock, Value | $ 23,000 | $ 17,000 | |||||||
Warrants Issued During Period, Warrants | shares | 7,690 | ||||||||
Interest Rate on Convertible Note | 6.00% | ||||||||
Debt Instrument, Convertible, Conversion Price | (per share) | $ 0.80 | $ 1.35 | $ 1.04 | ||||||
Sale of Stock, Price Per Share | $ / shares | $ 0.70 | $ 0.80 | |||||||
Commission Paid to Agents | $ 157,800 | ||||||||
Stock Issued During Period, Shares, Issued for Services | shares | 243,275 | ||||||||
Equity Issuance, Per Share Amount | $ / shares | $ 0.80 | ||||||||
Warrants Issued During Period, Value | $ 50,000 | ||||||||
Increase in additional paid in capital | $ 1,000,000 | $ 50,000 | $ 1,897 | ||||||
Fair value of common stock and warrant issued | 2,872,000 | ||||||||
Sale of Stock, Number of Shares Issued in Transaction | shares | 1,428,571 | ||||||||
Sale of Stock, Consideration Received on Transaction | $ 1,000,000 | ||||||||
Proceeds from Issuance Initial Public Offering | 11,405,000 | ||||||||
Options exercised | 21,000 | 33,000 | |||||||
Stock-based compensation | 333,000 | $ 370,000 | |||||||
Class of Warrant or Right, Exercises in Period | shares | 4,044,606 | 4,044,606 | |||||||
Class of Warrant or Right, Exercises in Period, Intrinsic Value | |||||||||
Proceeds from Warrant Exercises | 2,295,000 | ||||||||
Warrants exercised | 2,295,000 | ||||||||
Stock options granted to employees and directors [Member] | |||||||||
Class of Stock [Line Items] | |||||||||
Stock-based compensation | 286,000 | 356,000 | |||||||
Stock options granted to consultant [Member] | |||||||||
Class of Stock [Line Items] | |||||||||
Stock-based compensation | 47,000 | 14,000 | |||||||
Unrecognized stock-based compensation [Member] | |||||||||
Class of Stock [Line Items] | |||||||||
Stock-based compensation | 157,000 | 453,000 | |||||||
ASU 2014-13, Consolidation (Topic 810) Measuring the Financial Assets and the Financial Liabilities of a Consolidated Collateralized Financing Entity [Policy Text Block] | |||||||||
Class of Stock [Line Items] | |||||||||
Stock-based compensation | $ 36,000 | $ 83,000 | |||||||
Convertible Debt Securities [Member] | |||||||||
Class of Stock [Line Items] | |||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities | shares | 7,940 | ||||||||
Convertible debentures were converted into common stock, Value | $ 5,000 | ||||||||
Interest Rate on Convertible Note | 6.00% | ||||||||
Public Offering [Member] | |||||||||
Class of Stock [Line Items] | |||||||||
Commission Paid to Agents | $ 560,000 | ||||||||
Stock Issued During Period, Shares, Issued for Services | shares | 1,226,360 | ||||||||
Equity Issuance, Per Share Amount | $ / shares | $ 0.875 | ||||||||
Warrants Issued During Period, Value | $ 280,000 | ||||||||
Increase in additional paid in capital | 280,000 | ||||||||
Fair value of common stock and warrant issued | $ 10,623,000 | ||||||||
Number of closing units | shares | 17,144,314 | ||||||||
Proceeds from Issuance Initial Public Offering | $ 632,527 | $ 12,000,000 | |||||||
Number of options exercised | shares | 903,610 | ||||||||
Share Price | $ / shares | $ 0.70 | $ 1 | |||||||
Common Stock [Member] | |||||||||
Class of Stock [Line Items] | |||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities | shares | 17,036 | 17,036 | |||||||
Fair value of common stock and warrant issued | $ 1,460,000 | ||||||||
Number of options exercised | shares | 50,000 | 60,000 | 60,000 | ||||||
Warrants exercised (in shares) | shares | 4,044,606 | 4,044,606 | |||||||
Common Stock [Member] | Public Offering [Member] | |||||||||
Class of Stock [Line Items] | |||||||||
Fair value of common stock and warrant issued | $ 9,187,000 | ||||||||
Warrant [Member] | |||||||||
Class of Stock [Line Items] | |||||||||
Fair value of common stock and warrant issued | 437,000 | ||||||||
Class of Warrant or Right, Exercises in Period | shares | 4,044,606 | 4,044,606 | |||||||
Class of Warrant or Right, Exercises in Period, Intrinsic Value | |||||||||
Proceeds from Warrant Exercises | 2,295,000 | ||||||||
Warrant [Member] | Public Offering [Member] | |||||||||
Class of Stock [Line Items] | |||||||||
Fair value of common stock and warrant issued | 1,436,000 | ||||||||
Additional Paid-In Capital [Member] | |||||||||
Class of Stock [Line Items] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | 0 | 0 | |||||||
Proceeds from Stock Options Exercised | 21,000 | 33,000 | |||||||
Options exercised | $ 21,000 | 33,000 | |||||||
Warrants exercised | $ 2,295,000 |
Additional Paid-In Capital (Nar
Additional Paid-In Capital (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 12 Months Ended | ||
Mar. 27, 2019 | May 16, 2018 | Dec. 31, 2019 | Dec. 31, 2018 | |
Schedule of Additional Paid In Capital [Line Items] | ||||
Common stock, shares authorized | 200,000,000 | 200,000,000 | ||
Stock based compensation | $ 333 | $ 370 | ||
Class of Warrant or Right, Exercises in Period | 4,044,606 | |||
Class of Warrant or Right, Exercises in Period, Intrinsic Value | ||||
Proceeds from Warrant Exercises | 2,295 | |||
Warrants exercised | $ 2,295 | |||
Employees and Directors | ||||
Schedule of Additional Paid In Capital [Line Items] | ||||
Stock based compensation | $ 157 | |||
Additional Paid-In Capital [Member] | ||||
Schedule of Additional Paid In Capital [Line Items] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ 0.40 | $ 0.40 | ||
Warrants exercised | $ 2,295 | |||
2016 Stock Option Plan [Member] | ||||
Schedule of Additional Paid In Capital [Line Items] | ||||
Common stock reserved for issuance | 9,347,747 | |||
2016 Stock Option Plan [Member] | Additional Paid-In Capital [Member] | ||||
Schedule of Additional Paid In Capital [Line Items] | ||||
Stock based compensation | $ 333 | $ 345 | ||
Stock options granted to employees and directors [Member] | ||||
Schedule of Additional Paid In Capital [Line Items] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ 0.19 | |||
Stock based compensation | 286 | $ 356 | ||
Stock options granted to consultant [Member] | ||||
Schedule of Additional Paid In Capital [Line Items] | ||||
Stock based compensation | 47 | 14 | ||
Unrecognized stock-based compensation [Member] | ||||
Schedule of Additional Paid In Capital [Line Items] | ||||
Stock based compensation | 157 | 453 | ||
ASU 2014-13, Consolidation (Topic 810) Measuring the Financial Assets and the Financial Liabilities of a Consolidated Collateralized Financing Entity [Policy Text Block] | ||||
Schedule of Additional Paid In Capital [Line Items] | ||||
Stock based compensation | $ 36 | $ 83 | ||
Deferred Share Units [Member] | ||||
Schedule of Additional Paid In Capital [Line Items] | ||||
Deferred Share Units Grants in Period | 271,740 | 287,355 | ||
Salaries, Wages and Officers' Compensation | $ 128 | $ 160 | ||
Performance and restricted share units | ||||
Schedule of Additional Paid In Capital [Line Items] | ||||
Performance and restricted share units issued | 53,846 | |||
Salaries, Wages and Officers' Compensation | $ 25 |
Income Tax (Narrative) (Details
Income Tax (Narrative) (Details) - USD ($) $ in Thousands | Dec. 31, 2019 | Dec. 31, 2018 |
Tax Credit Carryforward [Line Items] | ||
Non-refundable tax credits | $ 2,486 | $ 1,981 |
Expiring in 2026 [Member] | ||
Tax Credit Carryforward [Line Items] | ||
Non-refundable tax credits | 8 | |
Expiring in 2027 [Member] | ||
Tax Credit Carryforward [Line Items] | ||
Non-refundable tax credits | 10 | |
Expiring in 2028 [Member] | ||
Tax Credit Carryforward [Line Items] | ||
Non-refundable tax credits | 174 | |
Expiring in 2029 [Member] | ||
Tax Credit Carryforward [Line Items] | ||
Non-refundable tax credits | 152 | |
Expiring in 2030 [Member] | ||
Tax Credit Carryforward [Line Items] | ||
Non-refundable tax credits | 130 | |
Expiring in 2031 [Member] | ||
Tax Credit Carryforward [Line Items] | ||
Non-refundable tax credits | 138 | |
Expiring in 2032 [Member] | ||
Tax Credit Carryforward [Line Items] | ||
Non-refundable tax credits | 173 | |
Expiring in 2033 [Member] | ||
Tax Credit Carryforward [Line Items] | ||
Non-refundable tax credits | 115 | |
Expiring in 2034 [Member] | ||
Tax Credit Carryforward [Line Items] | ||
Non-refundable tax credits | 87 | |
Expiring in 2035 [Member] | ||
Tax Credit Carryforward [Line Items] | ||
Non-refundable tax credits | 102 | |
Expiring in 2036 [Member] | ||
Tax Credit Carryforward [Line Items] | ||
Non-refundable tax credits | 141 | |
Expiring in 2037 [Member] | ||
Tax Credit Carryforward [Line Items] | ||
Non-refundable tax credits | 270 | |
Expiring in 2038 [Member] | ||
Tax Credit Carryforward [Line Items] | ||
Non-refundable tax credits | 582 | |
Expiring in 2039 [Member] | ||
Tax Credit Carryforward [Line Items] | ||
Non-refundable tax credits | 404 | |
Undeducted research and development expenses with no expiration date [Member] | ||
Tax Credit Carryforward [Line Items] | ||
Non-refundable tax credits | 14,282 | 10,663 |
Canadian federal [Member] | ||
Tax Credit Carryforward [Line Items] | ||
Operating Loss Carryforwards | 23,101 | 14,934 |
Provincial [Member] | ||
Tax Credit Carryforward [Line Items] | ||
Operating Loss Carryforwards | $ 25,264 | $ 16,498 |
Revenues (Narrative) (Details)
Revenues (Narrative) (Details) $ in Thousands | 12 Months Ended |
Dec. 31, 2019USD ($) | |
Revenue from Contract with Customer [Abstract] | |
Transaction price allocated to the remaining performance obligation | $ 1,084 |
Research and development milestone payments | $ 4,169 |
Percentages of recognized in next three year | 60.00% |
Percentages of remaining recognized in next two years | 40.00% |
Commercial sales milestone payments | $ 28,376 |
Leases (Narrative) (Details)
Leases (Narrative) (Details) $ in Thousands | 12 Months Ended |
Dec. 31, 2019USD ($) | |
Leases [Line Items] | |
Operating lease expense | $ 152 |
Cash outflows from operating leases | $ 144 |
Weighted average remaining lease term | 6 years 2 months 12 days |
Weighted average discount rate for operating leases | 10.00% |
Related Party Transactions (Nar
Related Party Transactions (Narrative) (Details) - USD ($) $ in Thousands | 1 Months Ended | 12 Months Ended | ||
Mar. 27, 2019 | May 16, 2018 | Dec. 31, 2019 | Dec. 31, 2018 | |
Deferred Share Units [Member] | ||||
Related Party Transaction [Line Items] | ||||
Salaries, Wages and Officers' Compensation | $ 128 | $ 160 | ||
Options granted to Chief Executive Officer [Member] | ||||
Related Party Transaction [Line Items] | ||||
Salaries, Wages and Officers' Compensation | $ 67 | $ 75 | ||
Options granted to Chief Financial Officer [Member] | ||||
Related Party Transaction [Line Items] | ||||
Salaries, Wages and Officers' Compensation | 50 | 46 | ||
Options granted to former Vice President, Operations [Member] | ||||
Related Party Transaction [Line Items] | ||||
Salaries, Wages and Officers' Compensation | 29 | 24 | ||
Options Granted To Vicepresident Research And Development [Member] | ||||
Related Party Transaction [Line Items] | ||||
Salaries, Wages and Officers' Compensation | 29 | 54 | ||
Options granted to Vice- President, Business and Corporate Development [Member] | ||||
Related Party Transaction [Line Items] | ||||
Salaries, Wages and Officers' Compensation | 36 | 12 | ||
Options granted to non-employee directors [Member] | ||||
Related Party Transaction [Line Items] | ||||
Salaries, Wages and Officers' Compensation | 11 | |||
Director fees [Member] | ||||
Related Party Transaction [Line Items] | ||||
Salaries, Wages and Officers' Compensation | $ 231 | $ 250 |
Subsequent Event (Narrative) (D
Subsequent Event (Narrative) (Details) | Feb. 11, 2020CAD ($)$ / sharesshares | Oct. 26, 2018USD ($)shares | Oct. 22, 2018USD ($)$ / sharesshares | Dec. 31, 2018USD ($)shares | Feb. 11, 2020$ / shares | Dec. 31, 2019$ / shares |
Subsequent Event [Line Items] | ||||||
Proceeds from offering | $ 11,405,000 | |||||
Class of Warrant or Right, Exercises in Period | shares | 4,044,606 | |||||
Class of Warrant or Right, Exercises in Period, Intrinsic Value | ||||||
Public Offering [Member] | ||||||
Subsequent Event [Line Items] | ||||||
Number of closing units | shares | 17,144,314 | |||||
Share Price | $ / shares | $ 0.70 | $ 1 | ||||
Proceeds from offering | $ 632,527 | $ 12,000,000 | ||||
Number of common shares issued for options exercised | shares | 903,610 | |||||
Subsequent Event [Member] | Public Offering [Member] | ||||||
Subsequent Event [Line Items] | ||||||
Number of closing units | shares | 16,317,000 | |||||
Share Price | $ / shares | $ 0.50 | |||||
Proceeds from offering | $ 8,158,500 | |||||
Net proceeds from public offering | $ 7,400,000 | |||||
Exercise price of warrants | $ / shares | $ 0.75 | |||||
Amount of agent agency fee equal to percentage gross proceeds offering | 7.00% |
Adoption of New Accounting St_4
Adoption of New Accounting Standards - Schedule of adoption of ASC 842 on balance sheet (Details) - USD ($) $ in Thousands | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Operating lease right-of-use assets | $ 683 | ||
Total assets | 11,020 | $ 20,018 | |
Total current liabilities | 8,447 | 2,722 | |
Deferred lease obligations | 49 | ||
Operating lease liability | 692 | ||
Total liabilities | 10,727 | 10,031 | |
Total shareholders' equity | 293 | 9,987 | $ 3,829 |
Total liabilities and shareholders' equity | 11,020 | 20,018 | |
Accounting Standards Update 842 [Member] | |||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Operating lease right-of-use assets | 726 | ||
Total assets | 20,744 | ||
Total current liabilities | 2,849 | ||
Deferred lease obligations | 0 | ||
Operating lease liability | 599 | ||
Total liabilities | 10,708 | ||
Total shareholders' equity | 10,036 | ||
Total liabilities and shareholders' equity | 20,744 | ||
Restatement Adjustment [Member] | Accounting Standards Update 842 [Member] | |||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Operating lease right-of-use assets | $ 726 | ||
Total assets | 726 | ||
Total current liabilities | 127 | ||
Deferred lease obligations | (49) | ||
Operating lease liability | 599 | ||
Total liabilities | 677 | ||
Total shareholders' equity | 49 | ||
Total liabilities and shareholders' equity | 726 | ||
Previously Reported [Member] | Accounting Standards Update 842 [Member] | |||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Operating lease right-of-use assets | 0 | ||
Total assets | 20,018 | ||
Total current liabilities | 2,722 | ||
Deferred lease obligations | 49 | ||
Operating lease liability | 0 | ||
Total liabilities | 10,031 | ||
Total shareholders' equity | 9,987 | ||
Total liabilities and shareholders' equity | $ 20,018 |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Leasehold Improvements and Equipment (Details) | 12 Months Ended |
Dec. 31, 2019 | |
Laboratory and office equipment [Member] | |
Property, Plant and Equipment [Line Items] | |
Property, Plant and Equipment, Depreciation Methods | declining balance method |
Property Plant and Equipment, Estimated Useful Live Depreciation Methods Percentage | 20.00% |
Computer equipment [Member] | |
Property, Plant and Equipment [Line Items] | |
Property, Plant and Equipment, Depreciation Methods | declining balance method |
Property Plant and Equipment, Estimated Useful Live Depreciation Methods Percentage | 30.00% |
Leasehold improvements [Member] | |
Property, Plant and Equipment [Line Items] | |
Property, Plant and Equipment, Depreciation Methods | straight-line method |
Property Plant And Equipment, Estimated Useful Live Depreciation Methods Description | over the lease term |
Manufacturing equipment [Member] | |
Property, Plant and Equipment [Line Items] | |
Property, Plant and Equipment, Depreciation Methods | straight-line method |
Manufacturing equipment [Member] | Minimum [Member] | |
Property, Plant and Equipment [Line Items] | |
Property, Plant and Equipment, Useful Life | 5 years |
Manufacturing equipment [Member] | Maximum [Member] | |
Property, Plant and Equipment [Line Items] | |
Property, Plant and Equipment, Useful Life | 10 years |
Leasehold improvements and Eq_4
Leasehold improvements and Equipment - Schedule of Leasehold Improvements and Equipment (Details) - USD ($) $ in Thousands | Dec. 31, 2019 | Dec. 31, 2018 |
Property, Plant and Equipment [Line Items] | ||
Cost | $ 9,475 | |
Accumulated Depreciation | 3,110 | |
Property, Plant and Equipment, Net | 6,365 | $ 6,248 |
Manufacturing equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Cost | 4,657 | |
Accumulated Depreciation | 879 | |
Property, Plant and Equipment, Net | 3,778 | 3,512 |
Laboratory and office equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Cost | 1,368 | |
Accumulated Depreciation | 870 | |
Property, Plant and Equipment, Net | 498 | 562 |
Computer equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Cost | 125 | |
Accumulated Depreciation | 85 | |
Property, Plant and Equipment, Net | 40 | 39 |
Leasehold improvements [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Cost | 3,325 | |
Accumulated Depreciation | 1,276 | |
Property, Plant and Equipment, Net | $ 2,049 | $ 2,135 |
Long-term debt - Term loan (Det
Long-term debt - Term loan (Details) - USD ($) $ in Thousands | Dec. 31, 2019 | Dec. 31, 2018 |
Other Liabilities Disclosure [Abstract] | ||
Term loan facility | $ 1,005 | $ 1,502 |
Secured loan | 192 | 330 |
Total debt | 1,197 | 1,832 |
Less: current portion | 727 | 692 |
Total long-term debt | $ 470 | $ 1,140 |
Long-term debt - Term loan prin
Long-term debt - Term loan principal repayments (Details) - Dec. 31, 2019 $ in Thousands, $ in Thousands | CAD ($) | USD ($) |
Other Liabilities Disclosure [Abstract] | ||
2020 | $ 945 | $ 727 |
2021 | $ 610 | $ 470 |
Convertible Debentures - Schedu
Convertible Debentures - Schedule of Convertible Debt (Details) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2019CAD ($) | Dec. 31, 2019USD ($) | Dec. 31, 2018USD ($) | |
Convertible Debt [Abstract] | |||
Face value of the convertible debentures | $ 5,835,000 | $ 5,556,000 | |
Transaction costs | $ (1,237) | (952,000) | (907,000) |
Accretion | 759,000 | 398,000 | |
Convertible Debt | $ 5,642,000 | $ 5,047,000 |
Convertible Notes - Schedule of
Convertible Notes - Schedule of proceeds of equity components based on fair value (Details) $ in Thousands | 12 Months Ended |
Dec. 31, 2019USD ($) | |
Debt Instrument [Line Items] | |
Gross proceeds of units | $ 3,200 |
Transaction costs of units | 328 |
Net proceeds of units | 2,872 |
Common stock [Member] | |
Debt Instrument [Line Items] | |
Gross proceeds of units | 1,627 |
Transaction costs of units | 167 |
Net proceeds of units | 1,460 |
Warrants [Member] | |
Debt Instrument [Line Items] | |
Gross proceeds of units | 487 |
Transaction costs of units | 50 |
Net proceeds of units | 437 |
Convertible notes [Member] | |
Debt Instrument [Line Items] | |
Gross proceeds of units | 1,086 |
Transaction costs of units | 111 |
Net proceeds of units | $ 975 |
Convertible Notes - Schedule _2
Convertible Notes - Schedule of Components of the Convertible Notes (Details) - USD ($) $ in Thousands | Dec. 31, 2019 | Dec. 31, 2018 |
Convertible Notes [Abstract] | ||
Attributed value of net proceeds to convertible notes | $ 975 | $ 975 |
Accretion | 280 | 98 |
Convertible notes | $ 1,255 | $ 1,073 |
Capital Stock - Schedule of Sto
Capital Stock - Schedule of Stock by Class (Details) - USD ($) $ / shares in Units, $ in Thousands | Dec. 31, 2019 | Dec. 31, 2018 |
Stockholders' Equity Note [Abstract] | ||
Common stock, shares authorized | 200,000,000 | 200,000,000 |
Common stock, par value per share (in dollars per share) | $ 0.00001 | $ 0.00001 |
Preferred Stock, Shares Authorized | 20,000,000 | 20,000,000 |
Preferred Stock, Par or Stated Value Per Share | $ 0.00001 | $ 0.00001 |
Common stock, shares, issued | 93,942,652 | 93,477,473 |
Common Stock, Value, Issued | $ 1 | $ 1 |
Capital Stock - Schedule of pro
Capital Stock - Schedule of proceeds of equity components based on fair value (Details) $ in Thousands | 12 Months Ended |
Dec. 31, 2019USD ($) | |
Class of Stock [Line Items] | |
Gross proceeds of units | $ 3,200 |
Transaction costs of units | 328 |
Net proceeds of units | 2,872 |
Common stock [Member] | |
Class of Stock [Line Items] | |
Gross proceeds of units | 1,627 |
Transaction costs of units | 167 |
Net proceeds of units | 1,460 |
Warrants [Member] | |
Class of Stock [Line Items] | |
Gross proceeds of units | 487 |
Transaction costs of units | 50 |
Net proceeds of units | 437 |
Public Offering [Member] | |
Class of Stock [Line Items] | |
Gross proceeds of units | 12,634 |
Transaction costs of units | 2,011 |
Net proceeds of units | 10,623 |
Public Offering [Member] | Common stock [Member] | |
Class of Stock [Line Items] | |
Gross proceeds of units | 10,926 |
Transaction costs of units | 1,739 |
Net proceeds of units | 9,187 |
Public Offering [Member] | Warrants [Member] | |
Class of Stock [Line Items] | |
Gross proceeds of units | 1,708 |
Transaction costs of units | 272 |
Net proceeds of units | $ 1,436 |
Additional Paid-In Capital - Sc
Additional Paid-In Capital - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) - $ / shares | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
Schedule of Additional Paid In Capital [Line Items] | ||
Exercise price | $ 0.69 | $ 0.74 |
Expected volatility | 64.00% | 5.90% |
Expected life | 5 years 7 months 17 days | 5 years 7 months 17 days |
Risk-free interest rate | 2.18% | 2.73% |
Dividend yield |
Additional Paid-In Capital - _2
Additional Paid-In Capital - Schedule of Stock Option Activity to Employees and Directors (Details) - $ / shares | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
Schedule of Additional Paid In Capital [Line Items] | ||
Exercise price | $ (0.69) | $ (0.74) |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, End of Period | 4,014,818 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, End of Period | $ 0.70 | |
Share-based Payment Arrangement, Option [Member] | ||
Schedule of Additional Paid In Capital [Line Items] | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning of Period | 3,854,818 | 2,939,818 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning of Period | $ 0.68 | $ 0.65 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period | 100,000 | 1,250,000 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ 0.69 | $ 0.74 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | (37,500) | (175,000) |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price | $ (0.66) | $ (0.69) |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period | (402,500) | (100,000) |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price | $ (0.67) | $ (0.52) |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | (50,000) | (60,000) |
Exercise price | $ (0.41) | $ (0.56) |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, End of Period | 3,464,818 | 3,854,818 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, End of Period | $ 0.68 | $ 0.68 |
Additional Paid-In Capital - _3
Additional Paid-In Capital - Schedule of Stock Option Activity to Consultants (Details) | 12 Months Ended |
Dec. 31, 2019$ / sharesshares | |
Schedule of Additional Paid In Capital [Line Items] | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, End of Period | shares | 4,014,818 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, End of Period | $ / shares | $ 0.70 |
Consultant's stock options [Member] | |
Schedule of Additional Paid In Capital [Line Items] | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning of Period | shares | 50,000 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning of Period | $ / shares | $ 0.73 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period | shares | 500,000 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares | $ 0.72 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, End of Period | shares | 550,000 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, End of Period | $ / shares | $ 0.72 |
Additional Paid-In Capital - _4
Additional Paid-In Capital - Schedule of Share-based Compensation, Stock Options, and Warrants or Rights Activity (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
Schedule of Additional Paid In Capital [Line Items] | ||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $ 0.69 | $ 0.74 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning of Period | 4,014,818 | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term | 5 years 7 days | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning of Period | $ 0.70 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value, Beginning of Period | $ 16,500 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number, Beginning of Period | 3,402,318 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price, Beginning of Period | $ 0.70 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value, Beginning of Period | $ 16,500 | |
Range 1 [Member] | ||
Schedule of Additional Paid In Capital [Line Items] | ||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $ 0.41 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning of Period | 275,000 | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term | 25 days | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning of Period | $ 0.03 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number, Beginning of Period | 275,000 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price, Beginning of Period | $ 0.03 | |
Range 2 [Member] | ||
Schedule of Additional Paid In Capital [Line Items] | ||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $ 0.58 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning of Period | 675,000 | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term | 1 month 2 days | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning of Period | $ 0.10 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number, Beginning of Period | 675,000 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price, Beginning of Period | $ 0.12 | |
Range 3 [Member] | ||
Schedule of Additional Paid In Capital [Line Items] | ||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $ 0.62 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning of Period | 150,000 | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term | 3 days | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning of Period | $ 0.02 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number, Beginning of Period | 150,000 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price, Beginning of Period | $ 0.03 | |
Range 4 [Member] | ||
Schedule of Additional Paid In Capital [Line Items] | ||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $ 0.66 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning of Period | 200,000 | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term | 4 months 28 days | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning of Period | $ 0.03 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number, Beginning of Period | 150,000 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price, Beginning of Period | $ 0.03 | |
Range 5 [Member] | ||
Schedule of Additional Paid In Capital [Line Items] | ||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $ 0.69 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning of Period | 100,000 | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term | 2 months 23 days | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning of Period | $ 0.02 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number, Beginning of Period | 25,000 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price, Beginning of Period | $ 0.01 | |
Range 6 [Member] | ||
Schedule of Additional Paid In Capital [Line Items] | ||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $ 0.70 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning of Period | 475,000 | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term | 4 months 6 days | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning of Period | $ 0.08 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number, Beginning of Period | 237,500 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price, Beginning of Period | $ 0.05 | |
Range 7 [Member] | ||
Schedule of Additional Paid In Capital [Line Items] | ||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $ 0.73 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning of Period | 525,000 | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term | 9 months 25 days | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning of Period | $ 0.10 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number, Beginning of Period | 525,000 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price, Beginning of Period | $ 0.11 | |
Range 8 [Member] | ||
Schedule of Additional Paid In Capital [Line Items] | ||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $ 0.76 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning of Period | 905,000 | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term | 1 year 10 months 13 days | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning of Period | $ 0.17 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number, Beginning of Period | 705,000 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price, Beginning of Period | $ 0.16 | |
Range 9 [Member] | ||
Schedule of Additional Paid In Capital [Line Items] | ||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $ 0.77 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning of Period | 359,818 | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term | 8 months 8 days | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning of Period | $ 0.07 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number, Beginning of Period | 359,818 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price, Beginning of Period | $ 0.08 | |
Range 10 [Member] | ||
Schedule of Additional Paid In Capital [Line Items] | ||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $ 0.78 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning of Period | 100,000 | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term | 14 days | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning of Period | $ 0.02 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number, Beginning of Period | 50,000 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price, Beginning of Period | $ 0.01 | |
Range 11 [Member] | ||
Schedule of Additional Paid In Capital [Line Items] | ||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $ 0.89 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning of Period | 250,000 | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term | 5 months 8 days | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning of Period | $ 0.06 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number, Beginning of Period | 250,000 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price, Beginning of Period | $ 0.07 |
Additional Paid-In Capital - _5
Additional Paid-In Capital - Schedule of Stockholders' Equity Note, Warrants or Rights, Activity (Details) | 12 Months Ended |
Dec. 31, 2018$ / sharesshares | |
Additional Paid in Capital [Abstract] | |
Class of Warrant or Right, Outstanding, Beginning of Period | shares | 4,070,902 |
Class of Warrant or Right, Outstanding, Weighted Average Exercise Price, Beginning of Period | $ / shares | $ 0.5646 |
Class Of Warrant Or Right Granted | shares | 12,954,397 |
Class Of Warrant Or Right Granted In Period Weighted Average Exercise Price | $ / shares | $ 0.9464 |
Class of Warrant or Right, Exercises in Period | shares | (4,044,606) |
Class of Warrant or Right, Exercises in Period, Weighted Average Exercise Price | $ / shares | $ (0.5675) |
Class of Warrant or Right, Expirations in Period | shares | (76,296) |
Class of Warrant or Right, Expirations in Period, Weighted Average Exercise Price | $ / shares | $ (0.5646) |
Class of Warrant or Right, Outstanding, End of Period | shares | 12,904,397 |
Class of Warrant or Right, Outstanding, Weighted Average Exercise Price, End of Period | $ / shares | $ 0.9470 |
Income Taxes - Schedule of Effe
Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
Income Tax Disclosure [Abstract] | ||
Statutory income taxes | $ (2,398) | $ (2,421) |
Net operating losses for which no tax benefits have been recorded | 1,189 | 1,185 |
Deficiency of depreciation over capital cost allowance | (178) | (236) |
Non-deductible expenses | 667 | 422 |
Undeducted research and development expenses | 820 | 1,167 |
Investment tax credit | (100) | (117) |
Income tax expense (benefit), total | $ 0 | $ 0 |
Income Taxes - Schedule of Defe
Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2019 | Dec. 31, 2018 |
Income Tax Disclosure [Abstract] | ||
Leasehold improvements and equipment | $ 440 | $ 418 |
Net operating losses carryforward | 6,396 | 4,170 |
Undeducted research and development expenses | 2,903 | 2,774 |
Non-refundable tax credits carryforward | 2,082 | 1,982 |
Deferred Tax Assets, Gross | 11,821 | 9,344 |
Valuation allowance | (11,821) | (9,344) |
Deferred Tax Assets, Net | $ 0 | $ 0 |
Revenues - Disaggregation of Re
Revenues - Disaggregation of Revenue (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
Disaggregation of Revenue [Line Items] | ||
Total revenues | $ 742 | $ 1,824 |
Research and development agreements [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenues | $ 742 | $ 1,824 |
Revenues - Schedule of Revenue,
Revenues - Schedule of Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | ||
Revenues | $ 742 | $ 1,824 |
Product and services transferred at point in time [Member] | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | ||
Revenues | 372 | 0 |
Products and services transferred over time [Member] | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | ||
Revenues | $ 370 | $ 1,824 |
Revenues - Schedule of Revenue
Revenues - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
Disaggregation of Revenue [Line Items] | ||
Revenues | $ 742 | $ 1,824 |
Europe [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 534 | 1,715 |
Canada [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | $ 208 | $ 109 |
Statement of Cash Flows Infor_3
Statement of Cash Flows Information - Schedule of Cash Flow, Supplemental Disclosures (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
Supplemental Cash Flow Information [Abstract] | ||
Interest paid | $ 465 | $ 476 |
Leases - Schedule of reconciles
Leases - Schedule of reconciles undiscounted cash flows for operating leases (Details) $ in Thousands | Dec. 31, 2019USD ($) |
Operating Leases | |
2020 | $ 150 |
2021 | 152 |
2022 | 156 |
2023 | 158 |
2024 | 161 |
Thereafter | 188 |
Total undiscounted lease payments | 965 |
Less: Interest | 273 |
Present value of lease liabilities | $ 692 |
Leases - Schedule of operating
Leases - Schedule of operating lease liabilities (Details) $ in Thousands | Dec. 31, 2019USD ($) |
Leases [Abstract] | |
Current portion of operating lease liability | $ 137 |
Operating lease liability | $ 555 |